Regulation of Nuclear Hormone Receptors by Corepressors and Coactivators: a Dissertation by Wu, Xiaoyang
University of Massachusetts Medical School 
eScholarship@UMMS 
GSBS Dissertations and Theses Graduate School of Biomedical Sciences 
2001-12-14 
Regulation of Nuclear Hormone Receptors by Corepressors and 
Coactivators: a Dissertation 
Xiaoyang Wu 
University of Massachusetts Medical School 
Let us know how access to this document benefits you. 
Follow this and additional works at: https://escholarship.umassmed.edu/gsbs_diss 
 Part of the Amino Acids, Peptides, and Proteins Commons, Chemical Actions and Uses Commons, 
Genetic Phenomena Commons, and the Hormones, Hormone Substitutes, and Hormone Antagonists 
Commons 
Repository Citation 
Wu X. (2001). Regulation of Nuclear Hormone Receptors by Corepressors and Coactivators: a 
Dissertation. GSBS Dissertations and Theses. https://doi.org/10.13028/h387-xd16. Retrieved from 
https://escholarship.umassmed.edu/gsbs_diss/106 
This material is brought to you by eScholarship@UMMS. It has been accepted for inclusion in GSBS Dissertations and 
Theses by an authorized administrator of eScholarship@UMMS. For more information, please contact 
Lisa.Palmer@umassmed.edu. 
REGULA TION OF NUCLEAR HORMONE RECEPTORS BY
COREPRESSORS AND COACTIV ATORS
A DISSERTATION PRESENTED
XIAOY ANG WU
Submitted to the Faculty of the
University of Massachusetts Graduate School of Biomedical Sciences , Worcester
In Partial Fulfillment of the Requirements for the Degree of:
DOCTOR OF PHILOSOPHY
DEPARTMENT OF BIOCHEMISTRY AND MOLECULAR PHARACOLOGY
December 14 , 2001
Dr. Alonzo Ross, Chairman of Committee
Dr. Kai Lin, Member of Committee
Dr. Anthony Imbalzano, Member of Committee
Dr. Janet Stein, Member of Committee
Dr. Anthony Hollenberg, Member of Committee
ACKNOWLEDGEMENT
First, I need to thank my mentor Dr. J. Don Chen, for his patient instructions and
unlimited support during all these years. I also need to thank people in the Chen lab
particularly Dr. Hui Li , for their technical help and stimulating discussions.
I am very grateful to the members of my graduate committee , Drs. Alonzo Ross
Kai Lin, Anthony Imbalzano and Janet Stein, for offering me the timely and insightful
suggestions not only for my thesis research but also for my overall pursuit of being a
scientist. Without their help, I can never be at this stage.
I thank my family, especially my parents, who have prepared me, trusted me and
encouraged me to do what I like to do for a career.
Finally, I have special thanks to my wife, Yu Chen. Her love and support have
been inseparable ingredients of my life and any accomplishments and I consider this my
greatest luck.
REGULATION OF NUCLEAR HORMONE RECEPTORS BY
COACTIV ATORS AND COREPRESSORS
Abstract
Nuclear hormone receptors (NHR) constitute a superfamily of ligand inducible
transcriptional activators that enable an organism to regulate development and
homeostasis through switching on or off target genes in response to stimuli reflecting
changes in environment as well as endocrine. NHRs include classical steroid hormone
receptors (GR, AR, ER and MR) and retinoid, thyroid hormone receptors. One long-term
goal of our lab is to understand the molecular mechanisms through which the
transcriptional activity ofNHRs is regulated.
Extensive studies in the past few years have revealed that in addition to the
dependence on ligand availability, the transcriptional activity of NHRs is also regulated
by two types of proteins: co activators and corepressors. In the absence of ligand, many
NHRs , including TR and RAR can actively repress target gene transcription with the help
of corepressors, proteins that physically interact with both NHRs and histone
deacetylases (HDACs). Functional interactions between NHRs and corepressors therefore
lead to tightly compact and transcriptionally non-permissive chromatin structures after
the removal of obstructive acetyl groups from histone tails by HDACs. On the other
hand, ligand binding stabilizes NHRs in a conformation that favors interaction with
proteins other than corepressors; many of these proteins are able to potentiate the
transcriptional activity of NHRs through various mechanisms, such as histone
acetylation, chromatin remodeling and recruitment of basal transcription machinery and
are collectively termed coactivators.
Two highly related corepressors , SMRT (silencing mediator of retinoid and
thyroid hormone receptors) and N-CoR (nuclear receptor corepressor), have been cloned.
This research in corepressor SMR T started by a systematic study of its subcellular
localization. We found that SMR T predominantly forms a specific nuclear punctuate
structure that does not appear to overlap with any other well-known subnuclear
domains/speckles. Although our searching for specific sequence signals that may
determine the specific speckle localization of SMRT did not yield conclusive results
, we
discovered the colocalization ofunliganded RAR and certain HDACs
, including HDAC1
4 and 5 , in the SMRT nuclear speckles. Moreover, SMRT is likely to be the organizer
of such speckles since it appears to be able to recruit other proteins into these speckles.
The presence of HDAC1 in the SMRT speckles suggests a direct association between
these two proteins , which has not been detected by previous biochemical analyses.
Interestingly, HDAC1 point mutants that are completely defective in deacetylase activity
failed to locate to SMRT nuclear speckles , while another partially active mutant
maintained the colocalization. These discoveries may indicate SMR T nuclear speckles as
novel nuclear domains involved in transcriptional repression. More physiologically
relevant support for this hypothesis arises from study of HDAC4 and 5. HDAC4 and 5
are potent inhibitors of transcriptional activator MEF2C. Nuclear presence of HDAC4/5
can block the activation of MEF2C , which is required during muscle differentiation.
Normally, HDAC4 is predominantly located in cytoplasm. However
, we found that in the
presence of SMRT overexpression , HDAC4 was found mostly in SMRT nuclear
speckles. This accumulation enhanced HDAC4 mediated inhibition on MEF2C
transcriptional activity in a transient transfection assay. SMRT overexpression also
resulted in accumulation of HDAC5 in the SMRT nuclear speckles compared to the
nuclear diffuse distribution in the absence ofSMRT. Again
, this accumulation ofHDAC5
in nuclear speckles correlated with enhanced inhibition of MEF2C. Taken together
, our
study suggested that instead of being merely a corepressor for NHRs , SMR T might
function as an organizer of a nuclear repression domain, which may be involved in a
broad array of cellular processes.
In contrast to the limited number of corepressors , numerous co activators have
been identified; the SRC (or p 160) family is relatively well studied. This family includes
three highly related members , SRC- , TIF2/GRIP1 , RAC3/AIB1/ACTR/p/CIP. Similar
domain structures are shared among these factors , with the most highly conserved region
the bHLH-PAS domain found within the N terminal 400 amino acid residues. This
study of RAC3 aims to identify the function of the highly conserved N terminal bHLH-
P AS domain by isolating interacting proteins through yeast two-hybrid screening. One
candidate gene isolated encodes the C terminal fragment of the human homologue of the
yeast protein MMS 19. Functional studies of this small fragment revealed that it
specifically interacted with human estrogen receptors (ERs) and inhibited ligand induced
transcriptional activity of ERs in the transient transfection assay. Then we cloned the
full-length human MMS19 cDNA and characterized the hMMS19 as a weak coactivator
for estrogen receptors in the transient transfection assay. Furthermore, when tested on
separate AF- 1 or AF-2 ofERs , hMMS19 specifically enhanced AF- 1 but had no effect on
AF -2. These results identified hMMS 19 as a specific coactivator for ER AF-
TABLE OF CONTENTS
Title Page
Signature Page
Acknowledgements
Abstract
Table of Contents V11
Abbreviations
CHAPTER I: BACKGROUND
1. SteroidlNuclear Receptors
2. SteroidlNuclear Receptor Corepressors
3. SteroidlNuclear Receptor Coactivators: SRC Family
4. Regulation of Nuclear Receptors by Coactivators and Corepressors: ER as a
model
Summary and Thesis Goals
CHAPTER II: MATERIALS AND EXPERIMENTAL PROCEDURES
1. SMRT Plasmids and Antibodies
2. Yeast Two-Hybrid Screening
3. Rapid Amplification ofcDNAS 5' Ends (RACE)
4. hMMS 19 Expression Plasmids
5. Northern Blot
6. GST-Pull Down Assay
V11
7. Site-Directed Mutagenesis
8. Cell Culture and Transient Transfection Assay
9. Indirect Immunofluorescence
CHAPTER III: RESULTS
III- I. SMRTe INHIBITS MEF2C TRANSCRIPTIONAL ACTIVITY BY TARGETING
HDAC4 AND 5 TO NUCLEAR DOMAINS
A. Subcellular localization ofSMRTe and N-CoR in cultured cells
B. Determinants of nuclear localization and speckle distribution of
SMRTe
C. SMRTe nuclear domain is unique among other nuclear structures
D. Association of SMRTe with RARa in vivo
E. Colocalization of SMRTe nuclear domains with other interacting
proteins
F. Interaction of SMRTe with class I HDACs
G. Interaction of SMRTe with class II HDACs
H. SMRTe enhances HDAC4/5-mediated transcriptional inhibition
on MEF2C
Summary
111-2. THE HUMAN HOMOLOGUE OF YEAST DNA REPAIR AND TFIIH
REGULATOR MMS 19 IS AN AF - 1 SPECIFIC COACTIV A TOR OF THE
ESTROGEN RECEPTOR
V11
A. Identification ofhMMS19 as a RAC3-interacting protein by yeast two-hybrid
screenIng
B. Expression of human MMS19
C. In vitro interaction ofRAC3 and hMMS19
D. The hMMS 19 C-terminal RS2. 1 fragment inhibits ER activation
E. HMMS19 interacts with ER
F. HMMS19 enhances AF- 1 activity ofER
Summary
III 3. FUNCTIONAL INTERACTION BETWEEN HMMS 19 AND RAC3 IN
ENHANCING ERAF- 1 ACTIVITY
A. hMMS 19 coactivation is independent on ERa Ser 118
phosphorylation
B. hMMS 19 cooperates with RAC3 to enhance ER transcriptional activity
C. Selective interaction between RAC3 and ER N-terminus
D. RAC3 (342-646) selectively interacts with nuclear receptors
terminus
Summary
CHAPTER IV: DISCUSSION
IV- I. FUNCTIONAL IMPLICATION OF SMRTe NUCLEAR SPECKLES
A. SMRTe as an organizer of a novel nuclear domain
B. Dynamic property of the SMRTe nuclear speckles
C. Biological functions of the SMRTe speckles
IV-2. FUNCTIONAL RELATION BETWEEN HMMS19 AND RAC3 AND ITS
IMPLICATION FOR REGULATION ESTROGEN RECEPTORS
A. Interaction ofhMMS 19 with RAC3 and functional significance ofRAC3
bHLH-PAS domain
B. Interaction of hMMS 19 with ER
C. Interaction of RAC3 with ER AF-
D. Other AF- 1 specific coactivators
E. Role of hMMS 19 in ER signaling
CHAPTER V: REFERENCES
CHAPTER VI: FIGURES
CHAPTER VII: REPRINTS 131
ACTR
AF- 1 or 2
AIB1
ART
atRA
bHLH
CaMK
CBP
CoRNR box
CTD
DBD
ERE
GRIP 1
GST
HAT
HDAC
HNF -
Abbreviation
Activator of thyroid receptor
Activation domain
Activation function 1 or 2
Amplified in breast cancer-
Androgen receptor
AHR nuclear translocator
All-trans retinoic acid
Basic helix-loop-helix
Calcium/calmodulin -dependent protein kinase
CREB binding protein
Corepressor nuclear receptor- interacting box
Carboxyl terminal domain
DNA binding domain
Estrogen receptor
Estrogen response element
Glucocorticoid receptor
Glucocorticoid receptor-interacting protein 1
Glutathione S transferase
Histone acetyl transferase
Histone deacetylase
Hepatocyte nuclear factor-
HRE
LBD
MAPK
MEF
MEF2
MMS
CoR
NR box
PAS
P/CAF
PCIP
PGC-
PPAR
RAC3
RAR
RD1 , 2 , 3 and 4
RID
RXR
SANT
SMRT
SRA
Hormone response element
Ligand binding domain
Mitogen-activated protein kinase
Mouse embryonic fibroblast
Myogenic enhancing factor 2
Methyl methanesulfonate
Mineralcorticoid receptor
Nuclear receptor corepressor
Nuclear receptor binding box
reriod Arn , Sim
p300/CBP associated factor
p300/CBP interacting protein
peroxisome proliferator activated receptor y coactivator 
Peroxisome proliferator activated receptor
Progestrone receptor
Receptor associated coactivator 3
Retinoic acid receptor
Repression domain 1 , 2 , 3 and 4
Receptor interacting domain
Retinoid X receptor
W13 CoR, IF lIB
Silencing mediator of retinoid and thyroid hormone receptor
Steroid receptor RNA activator
Xll
SRC- Steroid receptor coactivator-
TIF2 Transcription intermediary factor 2
Thyroid hormone receptor
TRAM - Thyroid hormone receptor activator molecule-
TSA Trichostatin A
VDR Vitamin D receptor
X11
CHAPTER I
BACKGROUND
Higher organisms including humans respond to changes in environment or
endocrine signaling by rapidly altering gene transcriptions. Steroid/nuclear receptors are
a family of transcriptional activators whose activity is regulated by the binding oftheir
cognate ligands , usually small lipophilic molecules including steroid hormones, thyroid
hormone and the active forms of vitamin A and D(1-3). In the absence ofligand binding,
most steroid/nuclear receptors are inactive, and some , most notably retinoic acid receptor
(RAR) and thyroid hormone receptor (TR), actively repress transcriptions of their target
gene. Ligand binding triggers the activation of receptors , so that they will now bind to
specific DNA sequence on the target gene promoters, the so-called hormone response
elements (HREs), and activate the transcription. Most cellular actions of steroid/nuclear
receptors occur in this way and are thus restricted in the nucleus, although cytoplasmic
signaling pathways of steroid/nuclear receptors do exist and may account for those
extremely rapid cellular effects mediated by these receptors(4 , 5).
During the last decade, our knowledge of steroid/nuclear receptors exploded in
three different areas. First, a plethora of molecules effecting the activation or repression
of target genes have been identified, including corepressors and coactivators. Second, a
mechanistic understanding of how steroid/nuclear receptors are activated by ligand
binding has been established through determination of crystal structures of receptors and
receptor-coregulator complexes. Third, targeted deletion in mouse has generated useful
/.". . . .'.
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models to unambiguously define the specific functions of individual receptors in a
mammalian organism. Combined together, these advances have offered significant
insights into steroid/nuclear receptor regulation of a broad array of physiological
processes. In this work, I will first give a brief introduction of our current knowledge of
steroid/nuclear receptors and their two important coregulators, corepressors and
coactivators. I will then use estrogen receptor (ER) as a model to explain how the
function of a receptor is regulated at different levels in vivo, with focus on the regulation
exerted through corepressors and coactivators , introducing questions that I address in my
thesis.
1. Steroid/nuclear receptors
The first steroid receptor, glucocorticoid receptor (GR) was cloned about 15 years
ago. Cloning of a few other steroid receptors and TR revealed an extensive homology and
led to the realization that these receptors form one family and the rapid expansion of this
family by homology-based cloning of new members with the similar structure. As a
result, many receptors were cloned without identified ligands and these receptors have
been called "orphan receptors . A total of about 40 mammalian receptors (including
isoforms for the same receptor) have been identified. Based on their dimerization and
DNA binding properties, these receptors can be divided into four sub classes(2). Class I
includes those steroid receptors , ER, androgen receptor (AR), progesterone receptor (PR),
GR and mineralcorticoid receptor (MR), which function in the form of ligand induced
homodimers and bind to HREs with inverted repeats of two half-sites. Class II includes
, RAR, vitamin D receptor (VDR) and peroxisome proliferator activator receptor
(PP AR), which form heterodimers with retinoid X receptor (RXR) and bind to HREs
c, 
with direct repeats of two half-sites. Class III include RXR and orphan receptors such as
hepatocyte nuclear factor-4 (HNF-4), which bind to direct repeats as homodimers.
Finally, Class IV includes all the other orphan receptors binding to extended core sites as
monomers.
Like most transcriptional activators , steroid/nuclear receptors are modular
proteins , consisting of a functionally separable DNA binding domain and transcriptional
activating domains. Furthermore, based on sequence and structure similarity, about six
modulatory regions can be found in a typical receptor, denoted as A, B , C , D , E and F
from N to C-terminus (Fig. 1). A/B is the most variable region among steroid/nuclear
receptors in terms of both size and sequences. Region C represents the highly conserved
DNA-binding domain (DBD), while region E overlaps with the ligand-binding domain
(LBD), which also contain residues responsible for dimerization. D is a small linker
domain between the DBD (C) and the LBD (E) called "hinge region , which usually
harbors a nuclear localization signal and also functions to provide some structure
flexibility to the overall receptor conformation. Two transcriptional activating domains
have been identified in most receptors , namely AF- 1 and AF-2 (for activation function 1
or 2) respectively. AF - I is constitutively active and locates in the A/B region; AF-
resides in the E/F and is active only when the receptor is bound with ligand. Both AF-
and AF-2 activate transcription probably by recruiting coactivators , proteins that interact
with and enhance the transcriptional activity of steroid/nuclear receptors. While many
AF -2 specific co activators have been isolated, very few AF - 1 specific coactivators are
known. Since AF-2 from different receptors appears to share some common coactivators
there may be a common theme underlying how AF-2 activates gene transcription, while
the mechanisms of AF- 1 activation could be more divergent considering the sequence
variation of A/B regions among different receptors. For example , the A/ region from
GR contains an acidic activating region(6 , 7) typically found in many transcriptional
activators including GAL4(8), GCN4(9) and VP16 (10, 11), suggesting a similar
activating mechanism to that of those activators. However, A/B region from ERs does not
i':
contain any acidic region(12), suggesting that a totally different mechanism may be used
by ER AF-
The transcriptional activity of steroid/nuclear receptors is attributable to their
interaction with corepressors and coactivators in the absence and presence of ligand
respectively (Fig. 2). Next I will focus on our current understanding of how corepressors
and co activators regulate the functions of steroid/nuclear receptors.
2. Steroid/nuclear receptor corepressors
It was long realized that unliganded TR and its viral oncogenic counterpart v-
ErbA as well as RAR actively repress transcription. Later, the repression domains in TR
and RAR were mapped to the LBD of each receptor(13). In an in vivo competition assay,
overexpression of the repression domain from TR/ reversed TR/ mediated
silencing, suggesting the existence oflimited cellular silencing mediator(s) or
corepressor(s)(14 , 15). Furthermore , overexpression of full-length TR/RAR inhibited the
transcriptional repression mediated by the respective repression domain fused with a
heterologous DNA binding domain. This inhibition occurred in the absence , but not in
the presence of ligand, suggesting that the corepressor(s) must dissociate from the
receptors upon ligand binding( 15). By yeast two-hybrid screening, two related
""'" ):
corepressors , SMRT and N-CoR were soon cloned(16 , 17). Both proteins interact with
unliganded RAR/TR as well as a number of orphan receptors, including COUP- TF (18
19)and RevErb(20 , 21), and all have been shown to be able to repress transcription. As
expected for a corepressor, SMRTIN-CoR was released from receptors upon ligand
binding.
Several lines of evidence indicate that SMRT and N- CoR are bonafide
corepressors for TR/RAR. First of all, mutations introduced into RAR/TR that disrupted
the interaction with SMRTIN-CoR also abolished the RAR/TR mediated transcriptional
repression(22J; on the other hand, single cell injection of antibodies against SMRTIN-
CoR relieved receptor-mediated repression(23 , 24). Furthermore , when overexpressed
SMR T C-terminus containing the receptor interacting domain but lacking any
transcriptional repression domain acts as a dominant negative to inhibit receptor-
mediated repression(22). Similar experiments also established SMRTIN-CoR as
corepressors for transcriptional factors Pit- l (25), PLZF(26 , 27), MyoD(28) as well as
antagonist-bound steroid receptors ER and PR(29-32), suggesting a general role of
SMRTIN-CoR in mediating transcriptional repression. This is confirmed by genetic
studies in mouse. Targeted knock-out ofN-CoR gene in mouse results in early embryonic
lethality(33). The knock-out mice exhibit impaired definitive eryhropoiesis, arrested T
cell development at the double-negative stage and defects in neuronal development.
Further studies indicated aberrant transcriptional regulation by TR as well as other
transcription factors in the affected tissues , confirming the role ofN-CoR as a corepressor
for genes under the control of specific DNA-binding repressors and the repression
mediated by specific steroid/nuclear receptors and several other classes of DNA binding
transcription factors.
SMRT and N-CoR share a similar domain structure (Fig. 3), suggesting functional
similarity between these two proteins. N-CoR has approximately 1 000 amino acid
residues at the N-terminus not found in the original SMRT; however, the recent cloning
of the full-length SMRT, SMRTe/SMRTa(34 , 35) revealed that SMRTe and N-CoR are
similar in size and homologous to each other throughout the peptide sequence. As
summarized in Figure 3 , there are 3 or 4 autonomous repression domains present in N-
CoR/SMRTE respectively. In addition, both proteins have a highly conserved SANT
domain at the N-terminus and two adjacent receptor interacting domains (RIDs) at the C-
terminus. Each SANT domain (~W13 CoR, and IFIIB) consists of two
repeats and is very likely a protein-protein interacting domain(36) although no interacting
partners have been identified so far.
Recent work identified molecular determinants in corepressor RIDs for receptor
interaction. Each RID contains one short peptide motif, or "CoRN box (37-39), with a
consensus sequence of LXXI/H IXXX IIL(39) where L is Leucine , I is Isoleucine, H is
Histidine and X can be any amino acid residue. Site-directed mutagenesis of the key
hydrophobic amino acid residues in CoRNR boxes abolished the interaction with
receptors , and synthetic peptides containing CoRNR box blocked the receptor-
corepressor interaction, indicating that CoRN boxes are suffcient and necessary in
mediating receptor binding. However, despite the conservation ofCoRNR boxes , SMRT
and N-CoR do not bind receptors with equal affnity. For example, N-CoR prefers TR
and RevErb , while SMRT interacts preferentially with RAR(40 , 41). Furthermore, the
, -: -
two CoRNR boxes (CoRNRl and CoRNR2) within a single corepressor do not contribute
equally to the binding of a specific receptor( 40). For example RA interacts more
strongly with CoRNRI than with CoRNR2, while RXR interacts exclusively with
CoRNR2. This may imply that the interaction between a corepressor and RAR
dimer can be coordinated by the simultaneous binding of CoRNRl and CoRNR2 to RAR
and RXR, respectively. These results also suggest that the flanking sequences of CoRNR
boxes may determine the interaction specificity with receptors(40, 42). For example
Cohen et al found an additional LxxLL motif in front ofCoRNR box 1 ofN-CoR, which
is not present in SMRT and appears to mediate the TR- specific interaction(42). The
structural basis for these corepressor-receptor interactions were studied by X-ray
crystallography and wil be discussed later.
Two possible mechanisms have been proposed to explain how SMRT and N-CoR
repress gene transcription( 43 44). First of all , SMRT and N-CoR may function to recruit
histone deacetylases (HDACs), enzymes that remove acetyl groups from histone tails
resulting in more tightly compacted chromatin structure that is inhibitory to
transcriptional activation. SMRT and N-CoR associate with the mSin3A-HDACll2
complex through a direct interaction with mSin3A(23 , 45 , 46), the same mSin3A-
HDAC1I2 complex had been reported as corepressors for Mad-Max and Mxi-Max
heterodimers(47 , 48). The mSin3A interacting domain in SMRT corresponds to one of
the autonomous repression domains(45). Furthermore, HDAC-specific inhibitor
trichostatin A (TSA) relieved SMRTIN-CoR mediated repression, indicating that HDAC
activity is involved in SMRTIN-CoR mediated transcriptional repression. In mammals
multiple HDACs have been cloned(49). Based on sequence homology, these HDACs can
be divided into three classes. Class I includes HDAC 1 3 and 8 , which resemble yeast
Rpd3p; Class II includes HDAC 4 , 7 , 9 and 10(50J, which are related to yeast
Hdalp; Class III has a single member Sir2 , which is NAD+ dependent and insensitive to
the Class I and II inhibitor TSA( 51 J. Interestingly, each repression domain of SMR TIN-
CoR associates with a distinct HDACs. SMRT repression domain 1 (RD1) indirectly
associate with HDAC1/2; RD2 directly interacts with HDAC3 , while RD3 and RD4
binds HDAC4 , 5 and 7(52 , 53J. However, only HDAC3 was found in the core SMRTIN-
CoR complex biochemically purified from nuclear extracts(54 , 55J, raising the possibility
that only HDAC3 is essential for SMRTIN-CoR function, while other HDACs may be
required in a gene specific manner. Taken together, these data suggest that SMRTIN-CoR
recruit multiple HDACs to repress transcription. Interestingly, recent data revealed that
SMRTIN-CoR is also necessary to activate the enzymatic activity ofHDAC3(56J,
suggesting a more complicated role ofSMRTIN-CoR in mediating transcriptional
repression instead of merely serving as a scaffold protein.
The second possible silencing mechanism ofSMRTIN-CoR is to disrupt the
transcriptional pre-initiation complex through direct interaction with general
transcriptional machinery. SMRTIN-CoR was found to directly interact with general
transcriptional factor TFIIB(57 , 58). The TFIIB interacting region ofSMRTIN-CoR also
corresponds to one ofthe autonomous repression domains. More importantly, N-CoR
disrupted the functional interaction between TFIIB and TAF 32(58), which is important
in forming a pre-initiation complex(59 , 60). Notably, the two mechanisms outlined
above are not mutually exclusive and may function simultaneously.
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3. Steroid/nuclear receptor coactivators: SRC family
The existence of steroid/nuclear receptor coactivators was proposed about a
decade ago based on the experiment of "squelching , where activated steroid/nuclear
receptors can interfere with or inhibit transcriptional activity of other steroid/nuclear
receptors. This phenomenon was explained by competition among activated
steroid/nuclear receptors for a limited pool of cellular factors(61), which led to extensive
search for such kind of factors based on the assumption that these factors should
physically bind to steroid/nuclear receptor in the presence of ligand. As a result
numerous factors that can bind to various steroid/nuclear receptors in the ligand-
dependent manner have been isolated; many of them are able to enhance the
transcriptional activity of the binding receptor and are therefore termed coactivators(62
63). Probably because of the approach used to clone these factors , nearly all ofthem are
AF-2 specific and only three AF- l specific co activators , the p68/p72 RNA helicase(64)
and the SRA , a RNA coactivator for steroid receptors(65), have been reported. Relatively
well studied among these co activators is the SRC (steroid receptor coactivator)
family(66), also called p160 family to indicate that it contains homologous members with
a molecular weight of 160 kilodaltons.
The SRC family includes three related members , SRC- 1(67), GRlPl/TIF2(68-70)
and RAC3/pCIP/AIBlIACTR/TRAM- 1(71-75). GRIP 1 and pCIP are the murine
orthologs of human TIF2 and RAC3 , respectively, while AIBl , ACTR and TRAM- 1 are
human polymorphic clones ofRAC3. Most of these factors (SRC- , GRIP 1 , RAC3 and
ACTR) were cloned by yeast two-hybrid screening using receptor LBDs as baits. For
example , SRC- l was cloned in a yeast two-hybrid screen for human proteins specifically
bound to PR-LBD. Others were isolated in in vitro assays looking for proteins associated
with immobilized receptor LBD in the presence of ligand. All of these proteins have been
shown to bind to multiple steroid/nuclear receptors in a ligand dependent manner and
enhance their AF-2 activity. For example , SRC- l interacts ligand-dependently with PR
, TR, RXR, GR and PPAR, and enhances AF-2 activity of these receptors.
Interestingly, recent evidence supports that SRC- 1 and TIF2 also functionally interact
with N-terminus of steroid receptors and enhance the activity of AF - 1 (76-78). SRC
factors may also function to coactivate other transcriptional activators, such as NF-
SMAD3 , AP- , TEF and MEF2(79-83), suggesting that they participate in multiple
cellular signaling pathways.
Through modulation of steroid/nuclear receptor activity, SRC coactivators play
important roles in growth and reproduction, development and differentiation. For
example , RAC3/pCIP knockout in mouse resulted in retarded growth, delayed puberty
and reduced female reproduction(84). In addition, the RAC3 (AIB1) gene is frequently
amplified in ER positive breast cancer cells , and an in vivo association between RAC3
and ER was detected in breast cancer cell line MCF-7(71 , 85), suggesting a pathological
role ofRAC3 in breast cancer.
The SRC family of co activators shares a common domain structure (Fig. 4). From
N- to C-terminus , each member contains a highly conserved bHLH-PAS domain, a
receptor-interacting domain (RID) and a transcriptional activating domain (AD). The N
terminal bHLH-PAS domain is the most conserved region among SRC family member.
The bHLH (basic helix-loop-helix) domain is found in many transcriptional activators
where it functions as a DNA-binding or dimerization surface(86). The PAS (Per, Arnt
Sim) domain was initially identified in Drosophila protein Period (Per) and Single-
minded (Sim) as well as a mammalian protein ARNT (AHR nuclear translocator)(87). It
is typically comprised of250-300 amino acids and contains a pair of highly degenerate
50 amino acid subdomains termed the A and B repeats. Similar domains were also found
in many important regulators of circadian rhythm and neural development(88). The
function of P AS domain in those proteins is believed to act as a regulatory domain by
mediating protein-protein interaction. In the case of AHR, the PAS domain also serves as
a binding surface for small-molecule ligands such as dioxin(89-91). However, functions
for bHLH-P AS domains of SRC family members remain largely unkown, other than it
is likely to mediate protein-protein interactions. Two recent reports demonstrated that the
GRIP1 bHLH-PAS domain interacts with MEF2C , and the SRC- 1 bHLH-PAS domain
interacts with TEF(82 , 83). In both cases , the bHLH-PAS domains recruited GRIP I and
SRC- l as coactivators to the transcriptional activators.
The RID of SRC coactivators contains key determinants for receptor interaction
namely NR boxes i , ii , iii , with the consensus sequence of LXXLL(92). Crystallographic
studies have detailed the molecular basis of interaction between liganded receptors and
coactivator peptide containing LXXLL motifs(93 , 94). Briefly, receptor LBD is
comprised of 12 helices and coactivator LXXLL peptide binds to a hydrophobic groove
on the receptor surface , usually made up of helix 3 , 4 , and 12. Helix 12 undergoes a
dramatic change in orientation upon ligand binding to generate the hydrophobic groove
for coactivator binding and, therefore, is the key determinant of the ligand-dependent
recruitment of coactivators. Biochemical and biophysical studies have shown that a
receptor dimer recruits only one coactivator(94-96), suggesting a coordinate binding of
distinct LXXLL motifs from the coactivator to the two receptor monomers. Interestingly,
each receptor shows preferential binding of distinct LXXLL motifs within a single SRC
coactivator. For example , in the case of TIF2 , motif I preferentially binds RXR
, while
motif ii prefers PP ARa(97). The molecular basis of such selectivity appears to be
provided by the flanking sequences of a specific LXXLL motif. The interacting abilities
of each LXXLL motif and their particular arrangement in SRC coactivators determines
the interactions of individual co activators to different receptors , and consequently, the
functional diversity among SRC coactivators. This diversity is obvious when considering
the distinct phenotypes of SRC- 1 and RAC3 knockout mice(84 , 98).
One major mechanism by which SRC co activators help to activate gene
transcription is histone acetylation. Just as histone deacetylation is linked to
transcriptional repression, increased acetylation oflysines in histone tails correlates with
transcriptional activation(99 , 100). For example , yeast transcriptional activator GCN5 is a
histone acetyl transferase (HAT)(lOI). The human GCN5 homologue, P/CAF (P300/CBP
associated factor) and its interacting protein CBP (CREB Binding Protein) both possess
HAT activity with differential substrate specificity( 1 02, 103 )-P /CAF selectively
acetylates H3 and H4 , while p300/CBP acetylates all core histones in mononuc1eosomes.
Both P/CAF and p300/CBP are known co activators for steroid/nuclear receptors(104
105). Furthermore , mutations that disrupt the HAT activity ofp300 or CBP abrogate the
ability of these co activators to enhance transcription mediated by ER(106) or TR-
RXR(107) on reconstituted chromatin templates 
in vitro suggesting that HAT activity is
necessary for their ability to coactivate steroid/nuclear receptors. Interestingly, SRC
co activators , SRC- 1 and ACTR possess inherent HAT activity on H3 and H4 in
'''' ''.
,:(C'':
mononucleosomes as well(74 , 108). Therefore , interaction of SRC with steroid/nuclear
receptors may lead to histone acetylation through HAT activities inherent to either SRC
co activators or CBP/p300 and/or P/CAF that are recruited to receptors by SRC
coactivators. This also implies that steroid/nuclear receptors may employ multiple HAT
activities to activate target gene or distinct HAT activities may be required for activating
specific genes( 1 09).
The C-terminal transactivation domain of SRC coactivators overlaps with the
CBP interacting domain, suggesting a central role ofCBP in mediating SRC coactivators
transcriptional activity. In addition to its HAT activity, CBP also facilitates gene
transcription by recruiting general transcriptional machinery through direct interaction
with TFIIB(110). Furthermore , SRC- 1 also binds to general transcriptional factors TBP
and TFIIB(lll). Although the functional consequences of these interactions are not clear
it' s likely that SRC coactivators can activate transcription through recruiting or
stabilizing the preinitiation complex. Indeed, SRC- l was able to potentiate PR
transactivation with non-chromatin templates in an in vitro system(112), suggesting an
activating mechanism independent on histone acetylation. In addition, a weak
trans activating domain on SRC coactivators at the far C-terminal end interacts with an
arginine methyltransferase that further potentiates receptor-mediated gene
activation(l13). Taken together, these results support SRC coactivators activate
transcription through multiple mechanisms.
4. Regulation of steroid/nuclear receptors by coactivators and corepressors:
ER as a model
In mammals , there are two estrogen receptors encoded by distinct genes and
referred to as ERa and ER ; they share structural and functional similarity but display
different tissue distributions(114). As other members of the steroid/nuclear receptor
superfamily, ERs are ligand-dependent transcriptional activators. In the absence of their
cognate ligand , 17 -estradiol , ERs are inactively complexed with heat-shock protein
hsp90(115- 117). Ligand binding causes the dissociation of the complex and formation of
receptor homodimers that activate target genes by binding to EREs, DNA sequences
consist of inverted repeats of half site GGTCA with a one-nucleotide spacer. Mouse
genetics have demonstrated the central role of ERs in the pleiotropic effects of estrogen
on growth, development and diseases. ERa knock-out (ERKO) mice are infertile. Female
mice do not ovulate and display defects in the development of ovaries , uteri and
mammary glands(118 , 119). Male mice show compromised sexual behavior and testes
degeneration at puberty(120, 121). ER knock-out mice (BERKO) display less severe
phenotypes but also have defects in fertility and reproductive tissue development(122).
SRC coactivators regulate both ER AF-I and AF-
Like many steroid/nuclear receptors, ERs contain two transcriptional activating
domains , AF- 1 in the N terminal domain and AF-2 in the C terminal ligand-binding
domain. AF-2 activity is dependent on the binding of estrogen and can be blocked by
estrogen antagonist while AF- 1 is constitutively active , which probably accounts for the
partial agonistic effect of some anti-estrogens including tamoxifen(123). Furthermore , the
activities of AF- 1 and AF-2 are dependent on the target gene promoter context and tissue
type(12 , 124 , 125), thus sometimes one activating domain accounts for most ofthe
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transcriptional activity exhibited by the full-length receptor. While in other cases, both
AF- l and AF-2 need to act synergistically to achieve the full activity of the intact
receptor(76 , 124). This promoter context and tissue type specificity may be due to the
spatial availability of specific coactivators for AF - 1 and AF - , respectively, on individual
promoters. However, while AF-2 activity can be largely accounted for by ligand
dependent recruitment of coactivators , including SRC coactivators , the precise molecular
mechanism through which AF - I participates in transcriptional activation remains to be
determined. Recent studies of SRC co activators demonstrate that these factors directly
bind to ER AF - 1 using regions other than the receptor interacting domain or NR
boxes(76- , 126). In the case ofSRC- , the AF- l interacting domain was mapped to the
middle region, amino acid residues 361- 1139(77), while the C terminal Glutamine-rich
region seems to be mediating the GRlPl interaction with ER AF- 1(78). Both SRC- l and
GRIP 1 have been shown to enhance the activity of ER AF - 1 and mediate the functional
interaction between ER AF- 1 and AF-2(77 , 78 , 127), providing new insights into the
molecular basis of AF- l activity as well as its synergy with AF-2. Nonetheless , the exact
molecular mechanism of how SRC coactivators synergistically activate ER AF- l and AF-
2 is unknown.
SRC coactivators are vrimary coactivators for ERs
As discussed previously, numerous AF-2 specific coactivators have been isolated
for steroid/nuclear receptors. In the case of ERs, those coactivators include SRC
coactivators , p300/CBP , P/CAF. A recently isolated multiprotein complex involved in
thyroid hormone receptor (TR) and vitamin D receptor (VDR) signaling (DRIP/TRAP
complex)(128 , 129) has also been implicated in ER function through the interaction of its
PBP/TRAp220/DRIP205 subunit with ER(130). The big question is then how these
coactivators coordinate to modulate ER function. Models of both combinatorial and
sequential recruitment of these co activators to ER have been proposed( 131). Recent
studies present a body of evidence supporting a sequential recruitment model where
different co activators are recruited in an orderly fashion to the promoters of endogenous
ER target genes following estrogen stimulation(132- 134). Using the technique of
chromatin immunoprecipitation, Shang et al found that distinct coactivators appear
sequentially on ER target gene promoter in MCF-7 cells following estradiol
treatment(132). Interestingly, SRC co activators are among the first co activators that
appear at the promoter and more importantly, recruitment of SRC co activators appear to
be suffcient to induce assembly of an ERa complex capable of gene activation. In an 
vitro system , Kim et al found that recruitment of SRC functional domains to gene
promoters by heterologous DNA binding domain is sufficient to assemble a coactivator
complex to activate transcription, while recruitment of CBP fragments capable of
interacting with SRC coactivators failed to activate transcription, suggesting that SRC
coactivators have to be recruited prior to the recruitment of CBP/p300(133). Similarly,
Liu et al found in vitro synergistic enhancement ofPR transcriptional activity by SRC-
and p300 requires pre-incubation ofPR-bound chromatin templates with SRC- 1 before
the addition of p300 , but not vice versa, confirming a sequential recruitment of SRC-
prior to p300(134). Taken together, these data clearly reveal that SRC coactivators are
primary assembling factors in forming the coactivator complex necessary for ER
transcriptional activity.
SRC coactivators integrate multivle events regulating ER activation
Activation of ERs is a multiple-step process regulated not only by the ligand
binding and the subsequent recruitment of coactivators including SRC co activators, but
also by a number of other events , including receptor dimerization(135), phosphorylation
(136- 138) and DNA binding(139). Interestingly, recruitment of SRC co activators appears
to be the step that integrates these regulatory events during receptor activation
supporting again an essential role of SRC co activators in regulating ER transcriptional
activity. For example , MAPK phosphorylation ofER at Serll4 activates ER and this
activation arises from stronger interaction of the phosphorylated ER with SRC- 1(126).
Furthermore , protein kinase signaling pathways also result in phosphorylation of SRC
co activators ( 140- 142). Increased interaction between phosphorylated AIB 1 and p300 has
been observed which accounts for the enhanced transcriptional activity of ER upon
activation of MAPK pathway, suggesting that AIB 1 is the conduit through which signals
from activated protein kinases are relayed to ERs(141). Receptor dimerization may also
affect transcriptional activity by interfering with coactivator binding. ERa and ER form
functional homodimers as well as heterodimers(143), the differential transcriptional
activity of these dimers may be caused by their differential affinity with SRC
coactivator(144). Finally, individual EREs mediate differential ER transcriptional
activity(139), which is probably because individual ERE sequences induce changes in
conformation of the DNA-bound receptor ER and influence AIBlITIF2
recruitment(145). Taken together, these studies indicate that the highly regulated
recruitment of SRC coactivators is the critical step in ER activation.
The coactivator and corepressors exchange on recevtors
ERs usually do not bind corepressor SMRTIN-CoR except in the presence of
certain antagonists(29 , 30). This discovery indicates that corepressors are also important
regulators ofER activity. Binding of SMRTIN-CoR to tamoxifen-bound ER may prevent
the partial agonistic effect oftamoxifen. Indeed, the ER antagonist 4-hydroxy-tamoxifen
(4-0HT) failed to activate ER-dependent transcription in wild-type mouse embryo
fibroblasts (MEFs) but acted as a full agonist in N-CoK/- MEFs(33). In addition, a
tamoxifen responsive ER-D351 Y mutant exhibits reduced interaction with SMRTIN-
CoR(146).
From the above discussions , the most important molecular event in
steroid/nuclear receptor signaling following ligand binding is probably the switch from
corepressor binding to coactivator binding. Such a ligand dependent switch is the key to
transform a receptor from a transcriptional repressor to an activator and therefore
understanding the molecular basis of this switch will provide invaluable insights into how
functions of steroid/nuclear receptors are regulated 
in vivo.
It is interesting to note that co activators and corepressors use quite similar motifs
to interact with receptor LBDs. Actually, the consensus sequence LXXIIH IXXX IlL of
CoRNR boxes from corepressors represents an extended helix compared to LXXLL , the
sequence found in NR boxes for coactivators. The similarity between CoRNR box and
NR box suggests that corepressors and coactivators may utilize overlapping interaction
surfaces on the receptors. This idea is supported by the observation that point mutations
of certain residues in helix 3 , 5 and 6 on receptor LBD structure disrupt interactions with
SRC coactivators as well as with corepressors(39). Then how can ligand binding
differentially affect corepressor binding compared to coactivator binding?
Crystallographic studies of receptor LBD-NR box peptide have provided a compelling
model to explain this(93 , 94). As mentioned before , ligand binding to LBD induces a
shift in position of helix 12 , which together with helix 3 , 4 and 5 , forms a hydrophobic
pocket on the receptor surface where LXXLL helix fits in. Due to the extended size of the
CoRNR box, it will not fit into the hydrophobic pocket because of the consequent
molecular clash between the extended helix and helix 12. Therefore, corepressor cannot
bind to liganded receptors. This model predicts a critical role of helix 12 in recruiting
coactivators as well as in releasing corepressors , both have been supported by
biochemical studies. Deletion of helix 12 in LBD domain usually abolishes its
recruitment of SRC coactivators(70, 147), while helix 12 ofRXR is inhibitory to
corepressor binding and deletion of it enhanced the ability of RXR to repress
transcription ( 148). Furthermore , the crystal structure of antagonist bound ER reveals that
helix 12 oriented in a position different from that of ligand bound ER, where it blocks the
coactivator LXXLL helix binding(93). Interestingly, while steroid receptors generally do
not interact with corepressors , antagonist bound steroid receptors have been reported to
be able to recruit SMRTIN-CoR, probably because ofthat the relocated helix 12 wil no
longer occlude their binding.
Summary and thesis goals
Corepressors SMRTIN-CoR and SRC coactivators are key regulators of the
transcriptional activity of steroid/nuclear receptors. Both classes of cofactors are modular
proteins containing receptor interacting domains and other domains functioning to recruit
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either repression or activation complexes, respectively. Their RIDs use similar core
motifs to interact with receptors on overlapping surfaces whose accessibility is reversibly
regulated by ligand binding, making it possible for a receptor to switch between a
transcriptional activator and repressor. It is clear now that both corepressors and
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coactivators function in large complexes. Understanding the molecular composition of
each complex and the functional interactions among subunits of each complex holds the
key to elucidate how the transcriptional activity of steroid/nuclear receptors is regulated.
The focus of my thesis research is to study the functional interactions between SMRT and
its associated proteins and try to isolate and characterize proteins that interact with RAC3
and participate in modulating receptor activity.
The amazing ability ofSMRTIN-CoR to interact with a large number ofHDACs
and help various transcriptional factors to repress gene transcription raised the possibility
that SMRTIN-CoR may act as scaffold protein in the nucleus. However, current evidence
supporting in vivo interaction between SMRTIN-CoR and HDACs arises primarily from
I j
biochemical analyses of cellular extracts , and it' s somewhat controversial. For example
although co-immunoprecipitation revealed the association of HDACl/2 and Class II
HDACs , HDAC4 , 5 , 7 in the SMRTIN-CoR complex, they are not present in the purified
SMRTIN-CoR complex. Clarification of the interaction between these HDACs and
SMR TIN-CoR may provide important insight into how SMR TIN-CoR mediates
transcriptional repression by steroid/nuclear receptors. Therefore , one specific aim of this
thesis research is to study the molecular interactions between SMRT and other proteins
that have been reported in the corepressor complex by immunofluorescence. During this
course of study, we found that SMR T predominantly forms a specific nuclear dot
structure that does not appear to overlap with any other well-known subnuclear
domains/speckles. We observed the colocalization ofunliganded RAR and certain
HDACs , including HDAC1 , 3 , 4 and 5 , in the SMRT nuclear speckles. The presence of
HDAC1 in the SMRT speckles suggests a direct in vivo association between these two
proteins that has not been detected by previous biochemical analysis. However, HDACI
point mutants defective in deacetylase activity lost colocalization with SMRT nuclear
speckles , suggesting that HDAC activity of HDAC 1 is required for its association with
SMRT. Interestingly, association with SMRT resulted in nuclear accumulation of
HDAC4 , which correlated with the enhanced inhibition ofMEF2C by HDAC4 in a
transient transfection assay. These discoveries revealed an unexpected functional aspect
of the interaction between SMR T and other proteins of the corepressors complex, which
is to recruit these proteins into a novel subnuclear domain important in transcriptional
repressIOn.
The central role of SRC co activators in steroid receptor activation attracts much
interest in these proteins. Nevertheless , the N-terminal bHLH-P AS is the most highly
conserved domain but does not have a clearly defined function in steroid/nuclear
receptors signaling. It' s very likely that this domain mediates interactions with additional
components of the coactivator complex. Therefore, identification of interacting partners
for bHLH-PAS domain may help to elucidate the composition as well as function of the
coactivator complex. The second focus of this thesis research is to identify proteins that
interact with the RAC3 bHLH-PAS domain by yeast two-hybrid screening. During this
study, we cloned the human homologue of yeast protein MMS19 as a protein that
specifically interacts with RAC3 bHLH-PAS domain. Unexpectedly, hMMS19 also
' ,
interacts directly with and functions as a specific coactivator for ERs. Unlike most
coactivators , hMMSl9 enhanced the AF- , but not AF-2 ofERs. So we concluded that
hMMS 19 is a specific coactivator for human estrogen receptors through enhancement of
AF- 1 activity.
The third specific aim is to try to understand the molecular mechanism by which
hMMS 19 enhances the transcriptional activity of ER AF - 1. First we studied whether this
enhancement involves TFIIH mediated phosphorylation of ERa Serll8 since hMMSl9
interacts with TFIIH and it has been previously reported that TFIIH was able to enhance
the transcriptional activity of ERa AF- 1 by phosphorylating Serl18. We found that
hMMS19 activates mutant ER AF- 1 where Serll8 has been changed to Ala, suggesting
that the recruitment of TFIIH and subsequent phosphorylation of Serll8 by TFIIH is not
involved. We demonstrated that hMMS 19 may enhance ER AF - 1 through cooperation
with RAC3 , whose ability in stimulating AF- 1 has been reported. Interestingly, we found
a novel region in RAC3 that binds directly to the N-terminus ofER as well as some other
nuclear receptors. Based on these discoveries, a model integrating functions of each
individual RAC3 domain was proposed to explain its ability to coactivate certain nuclear
receptors such as ER. Taken together, these studies contribute to our understanding of
coactivator complex by identifying maybe a new member and providing new insight into
how coactivator complex mediate the synergistic activation of AF- 1 and AF- , the two
transcriptional activating domains of steroid/nuclear receptors.
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Chapter II
Materials and Experimental procedures
SMRTe Plasmids and Antibodies
The mammalian expression vector ofSMRTe , pCMX-hSMRTe was made by
taking the Asp718/Xhol fragment from pCMX-Gal-hSMRT(I- IIII)(34) and cloning
into pCMX-SMRT(16). pCMX- CoR was a gift from Dr. M. Rosenfeld , pBJ5-HDACl
, 6 and pBJ5-HDAC4mut(S246/467/632A) were gifts from Dr. S. Shreiber. The MEF2
3X Luciferase reporter was a gift from Dr. E. Olson. pCMX-HA-HDAC3 was created by
taking the EcoRl fragment from pGEX-HDAC3 (a gift from Dr. W-M Yang) and cloning
into pCMX with an in-frame HA tag at the N-terminus.
Rabbit polyclonal antibodies against SMRT were described in Park et al(34), The mouse
anti-SMRT monoclonal antibody was obtained from GeneTex (San Antonio, Texas).
Monoclonal antibodies against Flag (Anti-FLAG M2) and HA epitope were from
KODAK and Santa Cruz. The fluorescein-conjugated goat anti-rabbit IgG was purchased
from Rockland Inc and the rhodamine-conjugated goat anti-mouse IgG was purchased
from Chemicon.
Yeast two-hybrid screening
The yeast two-hybrid screening was carried out as described previously(147).
Briefly, the pGBT-RAC3 (l-408) was used to screen a human placenta cDNA library in
pACT2 vector (CLONTECH) for RAC3 interacting proteins. After primary selection on
synthetic dropout media without tryptophan, leucine or histidine and supplemented with
50mM 3-aminotriazole , 25 positive clones were isolated, which were further tested for 
galactosidase expression by the liquid assay as described. The library plasmids from
'" ;,:; ,
positive clones were rescued and retransformed into yeast cells , together with the original
bait and other constructs , for further confirming the specificity of protein-protein
interaction.
Rapid Amplification of cDNA 5' ends (RACE)
An hMMS19 gene specific 3' primer: 5' CAT AAG ATA GGA GAT CTG GCT
GGG CAC CCA AGA CTG TC 3' , which contains the endogenous BglI restriction site
was used together with an adaptor from the manufacturer to amplify the extreme 5' -end
ofhMMS19 from the Hela cell MarathonTM ready cDNA (CLONTECH). Resulted
product was re-amplified using the same 3' primer and an internal adaptor from the
manufacturer, which has a NotI restriction site. Purified products were subcloned into
pBluescript vector utilizing the NotI and BglI site. Plasmids from 30 independent clones
were purified and sequenced.
Construction of hMMS19 expression plasmids
The original pACT2-RS2. 1 isolated by yeast two-hybrid screening was cut with
SalI/BglI the 700bp fragment released was assembled into SalIBamM digested pCMX
vector containing an in-frame HA tag. This results in pCMX-HA-RS2. 1. pCMX-HA-
hMMS19 was constructed by assembling the SalI/BglI fragment from RACE and the
BglI/NsiI fragment from AF007151 (Research Genetics) together into SalI/NsiI 
digested
pCMX-HA-RS2. 1 vector. pCMX-HA-hMMS19a was obtained by replacing the
Dra3INsiI fragment ofpCMX-HA-hMMSI9 with the same fragment from EST clone
BE206052 (IMAGE 3010660) (Incyte Genomic). All constructs were confirmed by
sequencmg.
Northern Blot
MTN blots (CLONTECH) of either total mRNAs from various cancer cell lines
or multiple human tissues were probed with 32 labeled random-primed DNA
corresponding to the NsiIBglI restricted 1.5kb fragment from the cloned hMMS19.
Hybridization was performed using the ExpressHyb solution (CLONTECH) as
recommended by the manufacturer. The blot was washed twice for 20 min in 2x SSC
/0. 1 % SDS at room temperature and subjected to autoradiography at -
GST -pull down assay
GST fusion proteins were expressed in E. coli BL-21 cells and purified by
standard glutathione agarose bead according to manufacturer s recommendation
(Pharmacia). S labeled proteins were made by the coupled in vitro transcription and
translation reactions using the T7-Quick reticulocyte lysate system (Promega). For the
GST pull down assay, 5 g of glutathione agarose bead-conjugated fusion protein were
incubated with 5 l of in vitro translated labeled protein with moderate shaking at
C overnight in binding buffer(149). The pellet was washed 4 times with the binding
buffer. Supernatant was carefully removed each time and in the end, bound protein was
eluted in SDS sample buffer by boiling 5 min and then subjected to SDS-P AGE and
autoradiogaphy.
Site directed mutagenesis
ER Serl18 mutants were generated with the Quick-change site-directed
mutagenesis system (Stratagene). Mutagenesis utilized a supercoiled, double stranded
DNA template with the insert of interest and two , synthetic , complementary
oligonucleotide primers containing the desired mutation. The primers extend during
temperature cycling by means of pfu Turbo DNA polymerase. Then the parental DNA
template is digested away with DpnI, which is specific for methylated DNA , thus
selecting for mutation-containing synthesized DNA. The sequences of mutant constructs
were confirmed by dideoxynucleotide chain-termination sequencing reactions using the
T7 Sequenase protocol (USB).
Cell culture and transient transfection assay
HEK293 cells were maintained in Dulbecco s modified Eagle s medium
(DMEM) supplemented with 10% fetal bovine serum (GIBCO). One day before
transfection, cells were seeded in 12-well plates at a density of 50 000 cells per well in
phenol-red free DMEM supplemented with 10% charcoal resin-stripped FBS.
Transfection was performed using a standard calcium/phosphate method as described
before (149). After ~ 10 hours , cells were washed with phosphate-buffered saline (PBS)
and re- fed with fresh medium containing either vehicle alone or vehicle plus ligands.
Cells were lysed 24 hrs after treatment for luciferase assay and 
galactosidase assays as
previously described.
Indirect immunofluorescence
Hela cells were grown on coverglasses (no. 1 , Erie Scientific , Portsmouth) in 12-
well plates. Immunocytochemistry was performed as described(149). Briefly, cells were
washed twice with PBS before fixing for I minute in pre-chilled methanol/acetone (1: 
on dry ice. Cells were blocked with 2% normal goat serum. After immunostaining, the
nuclei were counterstained 5 minutes with 1 j.g /ml DAPI (4' , 6-diamidino-
phenylindole dihydrochloride hydrae, Sigma). The coverglasses were then mounted on
Super Up-Rite microscope slides with ProLong Antifade Kit (Molecular Probes , Eugene
Oregon). The samples were analyzed using a Nikon immunofluorescence microscope.
The 2-D images were acquired using a cooled CCD camera and the MetaMorph program.
The images were false-colored with "Color Encode" command and processed using
PhotoShop or Canvas to adjust the displaying levels.
Chapter III
Results
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Chapter 111-
SMRTE INHIBITS MEF2C TRANSCRIPTIONAL ACTIVITY BY TARGETING
HDAC4 AND 5 TO NUCLEAR DOMAINS
A. Subcellular localization of SMRTe and N-CoR in culture cells
The steroid/nuclear receptor corepressors SMRTe and N-CoR mediate
transcriptional repression by unliganded retinoic acid and thyroid hormone receptors. To
provide insight into the function of SMRTe and N-CoR in cells , we analyzed the cellular
localization of three isoforms ofSMRT and N-CoR in mammalian cells using transient
expression and immunofluorescence microscopy.
Expression of SMR Te in Hela cells revealed that a majority of transfected cells
(80-90%) displayed exclusive nuclear speckle staining (Fig. 5 a), while about 10-20% of
transfected cells displayed overall speckle pattern in both cytoplasmic and nuclear
compartments (b). Similar distribution patterns were observed with monoclonal and
polyclonal antibodies , and in other cell types (data not shown). Also , immunostaining of
endogenous SMRTe showed nuclear speckle pattern (c), suggesting that such nuclear
speckles are not artifacts of protein overexpression. The existence of endogenous
cytoplasmic SMRTe is not conclusive due to high background of cytoplasmic staining
with the available antibodies.
Because the structure and function ofN-CoR is highly related to SMRTe, we also
analyzed cellular distribution ofN-CoR. We found N-CoR exclusively in nuclei (::99%
oftransfected cells) forming similar SMRTe speckles (Fig. 5, d). Because the expression
of SMRTe and N-CoR were controlled by the same promoter and staining intensity was
similar, it is unlikely that the difference in distribution is due to protein levels. We
suggest that the difference is intrinsic to SMRTe and N-CoR and distinct mechanisms
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may control SMRTe and N-CoR distribution.
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We then wished to determine the domain that determines SMRTe speckle
localization by analyzing a series of SMRTe deletion mutants. The N-terminal extended
domain between amino acids 1 to 1109 was located exclusively in the nucleus in a diffuse
pattern (Fig. 6 , panel b) suggesting that this domain contains nuclear localization signal
but lacks the speckle signal. Interesting, the highly conserved SNC-SANT domain was 'Iim
located mainly in the cytoplasm (panel c), indicating that nuclear localization signal is
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located outside of the SNC-SANT region. The original SMRT protein without the N-
terminal extended domain distributed mainly in nuclear speckles in a manner that is
similar to SMRTe (panel d) and consistent with an intact corepressors function.
Furthermore , the repression domain 3 (RD3) (formally SRDl) was located exclusively in
the nucleus with speckles (panel e), indicating that this domain contains a separated
nuclear localization signal and potent speckle localization signal. In contrast, the RD4
domain (formally SRD2) was located exclusively in the cytoplasm with pronounced
speckle pattern (panel)), suggesting that the RD4 contains a cytoplasmic speckle signal.
Interestingly, the steroid/nuclear receptor interacting domain alone (cSMRT) displayed a
diffuse, mostly cytoplasmic staining (panel 
g), 
indicating that it lacks a nuclear
localization signal. These data suggest that SMRTe contains multiple sequences for
regulating its precise subcellular localization.
C. SMRT nuclear domain is unique among other nuclear structures
The speckle distribution of SMRTe prompted us to investigate if SMRTe might
overlap with any known nuclear domains. Double immunofluorescence analysis of the
SMRT nuclear speckles with the splicing factor SC35 showed no colocalization (Fig. 7
panel a-d). Similarly, SMRTe did not colocalize with PML oncogenic domains (panel 
h). In addition, SMRTe did not colocalize with the nucleolus , condensed chromatin or
centromeres (data not shown). These data suggest that the SMRTe nuclear domains
represent a novel class of nuclear structures.
D. Association of SMRTe with RARa in vivo
To provide evidence for a role ofSMRTe in RA signaling, we examined the
association of SMRTe with RARa in vivo in the absence or presence ofRA. As
previously reported, RARa alone distributed diffusely in nucleoplasm (data not shown).
Interestingly, co-expression with SMRTe redistributed RARa into both the cytoplasmic
and nuclear speckles in the absence ofligand (Fig. 8 , panel a-c), demonstrating an in vivo
interaction between full-length SMRTe and unliganded RARa. Interestingly, atRA
treatment abolished this colocalization, leading to exclusive nuclear staining ofRARa
without affecting the SMRTe localization (pane d-f. This observation is consistent with
previous in vitro evidence that atRA induces dissociation of SMR T from the receptor. As
a control , no cytoplasmic colocalization between SMRTe and RXRa was observed (data
not shown), indicating specificity of this assay.
The dominant negative mutant cSMRT, which only contains the steroid/nuclear
receptor interaction domain, antagonizes transcriptional repression by Gal4-RARa fusion
protein(22). Because cSMRT is located primarily in the cytoplasm, we speculated that
this cytoplasmic cSMRT might either sequester unliganded Gal-RARa in the cytoplasm
or be translocated into the nucleus by Ga14-RARa. This was tested by double
immunofluorescence staining of cSMRT and Ga14-RARa. As previously reported, Ga14-
RARa alone was located exclusively in the nucleus (data not shown). Remarkably,
cSMRT sequestered the Ga14-RARa to the cytoplasm in the absence of ligand (Fig. 9
panel a-c), and all-trans RA treatment partially released this sequestration , rendering
accumulated nuclear localization of Ga14-RARa (panel d-j). These data suggest that
SMRTe can interact with unliganded RARa in vivo and that atRA can disrupt this
interaction. These data also suggest cellular compartmentalization may contribute to the
dominant effect of cSMRT.
E. Colocalization of SMRT nuclear domains with other interacting proteins
In addition to unliganded RA, SMR T also interacts with several other proteins
involved in diverse signaling pathways. These include the promyelocytic leukemia zinc
finger protein PLZF(26), ETO , the fusion partner of AML with t(8;21) translocation
(150), the mammalian homologue of the Drosophila Suppressor of Hairless CBFl(151),
the mammalian homologue of Drosophila chromatin binding protein BX42 (or Skip)
(152).
As expected, we found that PLZF and ETO colocalized precisely with the SMR 
nuclear domains (Fig. 10 , panel a-c, d-j). However, we found no evidence of association
between SMRT and CBFl (not shown). The distribution ofCBFl is nearly uniformly
located in the nucleus despite the presence or absence of SMRT overexpression.
Furthermore, in cells that contain cytoplasmic SMRT, CBF1 remained exclusively in the
nucleus uniformly. These data confirmed the in vivo interaction of SMRT with PLZF
and AML 1 , but not with CBF 
F. Interaction of SMRTe with class I HDACs
Biochemical evidence have suggested that HDAC1I2 and mSin3A form a stable
protein complex (153- 155). It has also been reported that SMRT and N-CoR form a
corepressor complex with mSin3A and HDAC1 (23 46). However, the purified
mSin3A-HDAC complex lacks SMRT and N-CoR(155). To help understand this
complexity and also to characterize potential SMRTe interactions with class I HDACs
---
we analyzed colocalization between SMRT and HDACs and mSin3A/B. In the absence
of SMR Te , HDAC 1 , 2 and 3 were located diffusely in the nucleoplasm (Fig. 11 , panel 
I and m). Interestingly, co-expression of SMRTe caused a distribution of HDAC 1 and
HDAC3 (panel d,j-l), but not HDAC2 (panelfh) or mSin3A (panel 
p) 
to distinctive
SMRTe nuclear speckles. We noted that HDAC3 co-expression appeared to partially
distort the structure of the SMRTe nuclear speckles. Because SMRTe clolocalized with
HDAC1 and HDAC3 in the absence ofmSin3A, and because SMRTe does not colocalize
with mSin3A, these data suggest an mSin3A-independent mechanism of interaction
between SMRTe and HDACI and 3 in vivo.
To further analyze the interaction between HDAC1 and SMRTe , we tested this
colocalization with three HDAC 1 point mutants whose HDAC enzymatic activities have
been disrupted to various degrees(156). The HDAC enzymatic activity depends on
conserved residues within the catalytic domain, and point mutation of these residues
disrupts HDAC activity(156). Three HDAC1 point mutants , H141A , H199A, and D176N
that are either partially defective (H141A) or completely void (H199A and D176N) of
HDAC activity were analyzed. We found that only the partially defective mutant H141A
(Fig. 12 , panel a-c) remained associated with SMRTe nuclear speckles in this assay,
while both Hl99A (panel d-f) and D176N (panel g-i) 
mutants , which lack HDAC activity
completely, failed to interact with SMRTe. These data indicate that the enzymatic activity
ofHDACI may be critical in the recruitment ofHDACl to SMRTe nuclear speckles.
G. Interaction of SMRTe with class II HDACs
- -
Recently, members of class II HDACs , HDAC4 , 5 , 7 were identified as SMRTIN-
CoR interacting proteins(52 , 54). We sought to confirm these interactions in vivo in the
double immunofluorescence assay. Consistent with a previous report, HDAC4 alone was
located primarily in the cytoplasm (Fig. 13A, panel a)(157). Strikingly, cotransfection
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where it colocalized precisely with SMRTe nuclear speckles (panel d). 
We estimated
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with SMRTe enhanced translocation ofHDAC4 from the cytoplasm into the nucleus
that in the absence ofSMRTe , about 70% of the transfected cells contained dormant
and nucleus (Fig. 13B). Strikingly, co-expression of SMRTe translocated HDAC4 into
,II
111
I:!II
iii:1!i
:;ill
, '
'I'i'
lit
cytoplasmic HDAC4 , and 30% contained almost equal HDAC4 staining in the cytoplasm
nuclear speckles in about 92% transfected cells , suggesting a mechanism of SMRTe-
dependent nuclear import and nuclear domain targeting ofHDAC4. This SMRTe-
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!IImediated nuclear import of wild type HDAC4 was even more pronounced than the
HDAC4 mutation S246/467/632A that abolishes 14- 3 binding in the cytoplasm(157).
not shown), suggesting SMRTe may playa role in the cytoplasmic-nuclear domain
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The HDAC4 S246/467/632A mutant also colocalized with SMRTe nuclear domain (data
trafficking ofHDAC4.
Similarly, we analyzed the co localization ofHDAC5 and SMRTe by double
immunofluorescence assay. HDAC5 alone was located diffusely in the nucleoplasm (Fig.
13A, panel e). There were only about 4% ofHDAC5 transfected cells contained HDAC5
dominant cytoplasmic staining (Fig. 13B). Strikingly, co-expression ofSMRTe
translocated HDAC5 almost completely from diffuse nucleoplasm staining into nuclear
speckles (Fig. 13A , panel.fh and Fig. 13B), again, suggesting a SMRTe-dependent
nuclear domain targeting ofHDAC5. We also tested the interaction ofSMRTe with
HDAC6 and found that HDAC6 was located exclusively in the cytoplasm and did not
show interaction with SMRTe (Fig. 13A, panel i-I). Overall , it can be concluded that
SMRTe selectively interacts with certain members of class II HDACs and it may play an
important role in regulating nuclear import ofHDAC4 , as well as nuclear domain
targeting ofHDAC4 and 5.
H. SMRT enhances HDAC4/5-mediated transcriptional inhibition on
MEF2C
MEF2C-mediated transcriptional activation is required for muscle cell
differentiation and such transcriptional activation is inhibited by over-expression of
HDAC4 and 5(158). Because SMRTe enhanced translocation of cytoplasmic HDAC4
into the nucleus , where HDAC4 can interact with MEF2C and inhibit its transcriptional
activity, we speculated that SMRTe might facilitate the ability ofHDAC4 to inhibit
MEF2C function by promoting nuclear localization ofHDAC4. This possibility was
tested by cotransfection of SMRTe and HDAC4 to determine their effects on MEF2C-
dependent activation of a luciferase reporter gene (Fig. 14). Consistent with previous
findings(159 , 160), we found that MEF2C alone strongly activated reporter gene
expression 40- 100 folds and that HDAC4 and 5 inhibited this activation by 2-4 folds
respectively. In contrast, HDAC1 , 2 , 3 and 6 did not have much effect on MEF2C
function (Fig. 14A). On the other hand, SMRTe alone also had only minor effect on the
MEF2C activity (Fig. 14B). However, cotransfection ofSMRTe and HDAC4
synergistically inhibited MEF2C activity by 20 folds. Similar effect was observed by co-
expression of SMRTe and HDAC5 , demonstrating that SMRTe may synergize with
HDAC4 and 5 to inhibit MEF2C-dependent transcriptional activation of target promoter.
Summary
Therefore , the inhibition of MEF2C transcriptional activation appears to correlate well
with targeting ofHDAC4 and 5 to SMRTe nuclear domains.
The corepressor SMRT and N-CoR interact with DNA-bound steroid/nuclear
receptor to mediate transcriptional repression by a mechanism involving histone
deacetylation. In this study, we have analyzed the subcellular localization of SMRTe , and
characterized the association of SMRTe with RAa and HDACs in vivo. We found that
SMRTe is localized within discrete cytoplasmic and nuclear speckles , and such
localization results in recruitment ofunliganded RARa and selective HDACs , HDAC1
4 and 5 to these nuclear domains. The colocalization ofHDAC3 , 4 and 5 with SMRTe
is consistent with previous biochemical findings. In particular, HDAC3 has been shown
to form a stable complex with SMRT and N-CoR(54 , 55 , 161), and HDAC3 can be
coprecipitated with HDAC4 and 5(162). The colocalization ofSMRTe with HDAC1 , but
not HDAC2 or mSin3A, is somewhat unexpected, because HDAC1 has been reported to
form a complex with SMRT indirectly via interaction with mSin3A(23 , 45). Consistent
with our findings , mSin3A does not colocalize well with N-CoR(163). Therefore , we
..t:';litl
suggest that HDACI may interact with SMRTe in vivo in an mSin3A-independent
manner. Perhaps protein modification or a yet-to-be-identified protein might stabilize this
in vivo interaction between HDAC1 and SMRTe.
Recruitment ofHDACI to SMRTe speckles depends on its histone deacetylase
activity, suggesting a potential role for SMRTe in regulating histone deacetylation.
SMRTe actively translocates HDAC4 from cytoplasm into the nucleus, and HDACS from
nucleoplasm into nuclear speckles. Accordingly, cotransfection of SMRTe with HDAC4
or synergistically inhibits MEF2C transcriptional activation. These data suggest a novel
mechanism by which SMRTe inhibits MEF2C transcriptional activity by recruiting
HDAC4 and to specific nuclear domains.
Chapter 111-
THE HUMAN HOMOLOGUE OF YEAST DNA REPAIR AND TFIIH
REGULATOR MMS19 IS AN AF- l SPECIFIC COACTIV ATOR OF THE
ESTROGEN RECEPTOR
A. Identification of hMMS19 as a RAC3-interacting protein by yeast two
hybrid screen
To identify proteins that interact with RAC3 N-terminal bHLH-PAS domain, we
conducted the yeast two-hybrid screening, using the RAC3 N-terminal aa 1-408 as bait to
screen a human placenta cDNA library. More than 2x10 clones were screened and from
which we isolated 25 positive colonies. Among the potential positive clones , one clone
designated RS2. 1 (RAC3 screening clone #2. 1) showed specific interaction with the bait
in yeast two-hybrid assay after retransformation of the rescued library plasmid (Fig.
15A). As controls , RS2. 1 did not interact with RAR, p53 or the bHLH-PAS domain of
mSim. When cotransformed into yeast cells with Ga14 DBD fused different regions of the
RAC3 N-terminus , RS2. 1 interacted with only the PAS-A/B domain and the interaction is
stronger than that with the bait (Fig. 15B). None of the separate bHLH, PAS-A or PAS-
domain interacted with RS2. 1. These data suggest that both P AS-A and P AS-B are
required for RS2. 1 interaction.
The RS2. 1 sequence matched a partial cDNA sequence in the Genbank
(Accession #: AF007151), whose function is unkown. However, the putative open
reading frame of AF007151 ends at about 260bp in front of where RS2. 1 starts.
Interestingly, the peptide sequence encoded by RS2. 1 shares significant homology with
the C-terminus of the yeast protein Mmsl9, a regulator of yeast TFIIH with functions in
both DNA repair and transcription ( 164 J. Further alignment of AF007151 and yMms 
indicated significant homology between these two proteins, suggesting that the full-
length RS2. 1 and AF007151 may encode the same protein. To clarify this , we blasted
both DNA sequences against dbEST database. Five EST clones that include the stop
codon region of AF007151 were found, and four of them have a single G insertion
between #937 and #938 nucleotide of AF00715. This G insertion will switch the reading
frame to the same as RS2. 1. These results were later confirmed by sequencing AF007151
and one of the EST clones. Therefore, we concluded that RS2. 1 and AF007151 are partial
cDNA sequences of the same gene transcript, and AF007151 may represent a natural
mutant of this gene.
The full-length RS2. 1 cDNA was then cloned by rapid amplification of the 5'
cDNA end (RACE). This resulted in a cDNA with a 3090 bp open reading frame
encoding a protein with 1030 amino acid residues. The original RS2. 1 encodes only the C
terminal 164 amino acid residues , which thus appears to be the RAC3 interacting domain.
On the contrary, the AF007151 sequence predicts a truncated protein at amino acid
residue 746 ofhMMS19 followed by a 33 aa sequence. Comparison with yeast Mms19
demonstrated a 42% overall similarity between RS2. 1 and yMms 19. Similar proteins
were also predicted from the genomic sequences of D. melanogaster C. elegans and A.
thaliana. Multiple-sequence alignment using ClustalW program (Fig. 16) indicates that
these proteins from different species can be roughly divided into three domains: the
highly conserved Nand C termini and the more divergent central region. From now on
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we will refer to the full- length hMMS 19 containing the AF007151 mutation as hMMS 19-
mt.
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B. Expression of human Mms19
ii,
Northern blot of various cancer cell lines and human tissues using the central 1.5
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kb ofhMMS19 as the probe detected a single band at about 4.0 kb (Fig. 17). This band is
't-
ubiquitously expressed in all cell lines and tissues analyzed. The transcript amount
appeared to be higher in brain, placenta, skeletal muscle and kidney than in heart, lung or
liver, while the amount looked quite even in cancer cell lines. By blast search against the
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high-throughput human genomic sequences , we found that human Mms19 gene maps to
chromosome 10q23. 3 region.
To determine the subcellular localization ofhMMS19 , we transiently transfected
HeLa cells with an expression plasmid carring HA-tagged hMMS 19 gene. By indirect
immunofluorescence using antibodies against HA epitope, we found that the HA-tagged
hMMS 19 protein is located exclusively in the cell nucleus (Fig. 18). This localization is
consistent with the presumed roles ofMMS19 in DNA repair and transcriptional
regulation through its functional interaction with TFIIH.
C. In vitro interaction ofRAC3 and hMMS19
To confirm the physical interaction between RAC3 and hMMS19 , we performed
GST pull down assays using GST-RAC3(1-407) and various GST-RAC3 fusion proteins
to pull down in vitro translated labeled full-length hMMS19, the C-terminal truncated
hMMS19-mt and the C-terminal RS2. 1 fragment. As shown in Fig. 19A , significant
amount of in vitro translated S labeled hMMS 19 and RS2. 1 were pulled down by GST-
RAC3 (1-407). In contrast, only residual amount ofhMMS19-mt were pulled down from
the input in the same experiment, suggesting the C terminal 164aa RS2. 1 fragment is the
RAC3-interacting domain.
Yeast two-hybrid assay has suggested that the RAC3 region responsible for the
interaction with hMMS19 is the combined PAS-A and PAS-B domain. This was again
confirmed by GST pull down (Fig. 19B). In this experiment, GST-RAC3-bHLH failed to
pull down any S labeled hMMS19a. In contrast, GST-PAS-A or GST-PAS-B alone
was able to pull down a small amount of hMMS 19 , suggesting a weak interaction
between hMMS19 and PAS-A or PAS-B separately. Strikingly, GST-PAS-A/ pulled
down labeled hMMS19 substantially. Similarly, GST-RAC3 (1-407) also pulled
down a substantial amount of hMMS 19. These data confirmed the results from yeast two-
hybrid assay, suggesting that both PAS-A and PAS-B are involved in the interaction with
hMMSI9.
D. The hMMS19 C-terminal RS2.1 fragment inhibits ER activation
Because RAC3 plays an important role in modulating ER activity in vivo
asked if RS2. 1 also has effects on ER activity. To test this possibility, HEK293 cells were
transiently transfected with estrogen receptor a (hERa) and a luciferase reporter gene
driven by estrogen responsive element (ERE). After transfection, 1713-estradiol induced a
strong activation of the reporter gene (Fig. 20A). Intriguingly, co-transfection of the
RS2. 1 fragment inhibited the ligand-dependent activation of hER a by about 4 fold (Fig.
20A). The inhibition is specifically mediated by ER since no inhibition was observed
when the reporter gene lacks the ERE (data not shown). Interestingly, the ligand
dependent activity of either RAa or TRI3 was not affected by RS2. 1 (Fig 20A),
suggesting that this inhibition is receptor specific.
To confirm the inhibition by RS2. 1 on ER activity, we transiently transfected
either hERa or hERI3 with increasing amount ofRS2. 1. A dose dependent inhibition was
observed on both hERa and hERI3 and the maximum repression were up to 9 and 6 fold
respectively (Fig 20B). These data suggest that MMS 19 may selectively affect both ERa
and ERI3 activity.
Because RS2. 1 represents the small C-terminal fragment ofhMMS19 that
interacts with both ER and RAC3 , RS2. 1 may inhibit ER activation as a dominant
negative mutant, disrupting the functional interaction between ER and RAC3. If this were
true , then overexpression ofRAC3 in the presence ofRS2. 1 may reverse the inhibition of
ER activity. So we examined the effect ofRS2. 1 on ERa in the presence ofRAC3
overexpression. Indeed, as shown in Fig. 20C , cotransfection ofRAC3 and RS2.
relieved RS2. 1 mediated inhibition of ERa in the transient transfection assay.
E. hMMS19 interacts with ER
The inhibition of ER activity by RS2. 1 prompted us to test if RS2. I interacts with
ER directly. GST-RS2. 1 was incubated with labeled hERa or hER in the absence of
ligand. In both cases , GST-RS2. I pulled down a significant portion of each S labeled
protein (Fig. 21A), indicating an interaction between RS2. 1 and ERs. Interestingly, in the
same experiment, only a slightly more than background level of S labeled RARa or
iii
were pulled down by GST -RS2. , consistent with the transient transfection data
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showing that RS2. 1 had no effect on either receptor s activity. We next examined
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in the presence of M 17 -estradiol or tamoxifen, a partial antagonist ofER. Neither
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I "whether ligand could effect this interaction. The GST pull down experiment was repeated
ligand was able detectably change this interaction (Fig. 2IB). Taken together, these data :!J
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suggest that the Mms19 interacts directly with ER in a ligand-independent manner.
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F. hMMS19 enhances AF- l activity ofER
Since RS2. 1 acts as a dominant negative to disrupt the functional interaction
between RAC3 and ER and inhibit the transcriptional activity ofER, we then asked
whether full-length hMMSI9 has any effect on ER activity. So we tested the effect of
full-length Mms19 on ER activation by a transient transfection assay. We found that full-
length Mmsl9 weakly, but consistently, enhanced the ligand-induced activity of hER a
(Fig. 22). In contrast, hMMS 19mt, which lacks the C-terminal RS2. I fragment, failed to
enhance ER activity, suggesting that the ability ofMMS19 to modulate ER activity
depends on ER-MMS19 interaction.
To dissect whether hMMS 19 coactivation is mediated through either the AF-
region or AF-2 region of hERa, we subcloned hERa A/B- C and CD-ElF regions
compared to full-length ER. As expected, the N-terminus is also active in the absence of
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separately into the same mammalian expression vector. In 293 cells , both isolated
domains can activate the reporter in the presence of ligand, although to a lesser extent
ligand. Strikingly, the activity of isolated ERa-N was enhanced 6-fold after co-
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transfection of hMMS 19 in the presence or absence of E2. On the other hand, AF-
activity was not affected by co-transfection ofMms19 (Fig. 23). These findings suggest
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111that Mms 19 may function as an AF - 1 specific coactivator of ERs.
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In this chapter, we have identified and characterized the human homologue ofthe
imt1l
yeast DNA repair and TFIIH regulator MMS19 as a RAC3/ER-interacting protein. The
human MMS19 interacts with the N-terminal PAS-A/B domain ofRAC3 through an
evolutionarily conserved C-terminal domain. Overexpression ofhMMS19 modulates ER-
mediated transcriptional activation by enhancing the AF - 1 function of ER. These data
reveal a novel function of hMMS 19 as an AF - I specific transcriptional coactivator of
estrogen receptor.
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Chapter 111-
FUNCTIONAL INTERACTION BETWEEN HMMS19 AND RAC3 IN
ENHANCING ER AF- l ACTIVITY
A. hMMS19 coactivation is independent on ERa Ser118 phosphorylation
The apparent association between hMMS 19 and TFIIH and the ability of TFIIH to
enhance ER activity by phosphorylating Ser 118 suggest a simple model where hMMS 
stimulates ER activity through enhanced Serl18 phosphorylation by recruiting TFIIH to
ER. This model predicts that the ability ofhMMS19 to enhance ER activity is dependent
on the presence of TFIIH kinase activity as well as Serl18 phosphorylation. To test this
model , we first mutated Serll8 to either Ala or Glu and tested whether hMMS 19 was
still able to enhance AF - 1 activity of either mutant. In transient transfection assay, it has
been shown that compared to wild-type ER, ER S 118A has a much reduced ligand-
dependent transcriptional activity consistent with its inability to be phosphorylated by
TFIIH at Serl18 , while ER S 118E is more active probably because it mimics the
constitutive phosphorylation state. Surprisingly, we found that ER N-terminus harboring
either mutation activates target gene slightly better than the wild type (Fig. 24),
suggesting that both mutations somehow weakly enhanced the AF- 1 activity.
Furthermore , coexpression of hMMS 19 was able to enhance the transcriptional activity 
either mutated ER N- terminus (Fig. 24). These results argues for a Serl18
---
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phosphorylatio independent pathway to activate at least the isolated ER AF- , which
likely involves hMMS19.
As a further support that hMMS 19 enhances ER AF - 1 in a TFIIH kinase activity-
independent manner, overexpression ofCDK7 and MATI , the two subunits ofTFIIH
responsible for phosphorylating ERa , failed to further enhance ER AF - I activity when
cotransfected with hMMS 19 (Fig. 25). Previous results have shown that CDK7 and
MATI overexpression is sufficient to enhance ligand-induced transcriptional activity of
full-length ERa.
B. hMMS19 cooperates with RAC3 to enhance ER transcriptional activity
hMMS19- interacting domain in ERa was mapped to the hinge region (D
domain) (Hui Li , unpublished data), indicating a lack of direct interaction between
hMMS19 and ERa N-terminus used in the previous experiments, which is comprised of
AlB- regions of ERa. Therefore , the observed enhancement on ERa AF- 1 activity by
hMMS 19 is very likely mediated by some other factors. Because hMMS 19 interacts with
RAC3 and RAC3 coactivates both AF- 1 and AF- , we investigated whether RAC3 could
be mediating functional interaction between ERa AF - 1 and hMMS 19.
Firstly, we checked ifRAC3 and hMMS19 together could activate ERa
transcriptional activity better than either factor alone. 293 cells were transiently
transfected with the ERE driven luciferase reporter gene and hERa or the separate ER-
or ER- , containing AF- 1 or AF-2 respectively. As expected, hMMS19 coexpression
enhanced the activity of AF - 1 as well as the full-length hERa in the presence ofligand
but had no effect on AF-2 alone (Fig. 26), while RAC3 coexpression enhanced the
transcriptional activity of all three activators. Interestingly, coexpression of hMMS 19 and
RAC3 together further enhanced the AF - I activity as well as the ligand induced hERa
activity (Fig. 26). Furthermore , the RAC3 truncation mutant, RAC3 N which lost the N-
terminal bHLH-PAS domain and therefore the ability to interact with hMMSI9, failed to
stimulate ER AF- I activity when transfected alone or together with hMMSl9 (Fig. 27).
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These results suggest that the functional interaction between hMMSl9 and RAC3 is 11'
necessary to coactivate ER AF -
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C. Selective interaction between RAC3 and ER N-terminus I:Y
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Direct interaction between ERa AF1 and SRC- 1/GRlPl has been shown by III
vitro GST pull down assay and further, the ERa AF- interacting domain in GRIP 1 was ::,1n
mapped to the extreme C-terminus. We sought to test the direct interaction between ERa
AF- l and RAC3 and also map the region in RAC3 responsible for the interaction. GST
fused various domains of RAC3 were incubated with in vitro translated S labeled ERa
terminus consisting of A/B-C regions of ERa. GST-RAC3 (342-646) pulled down a
significant amount of ER-N from the input, while other fusion proteins as well as
GST alone failed to do so (Fig. 28A, left panel), suggesting a specific interaction between
RAC3 (342-646) and ERa AF- I. To further confirm this interaction, we asked whether
RAC3 (342-646) interacts with full-length ER. GST -RAC3 (342-646) was incubated with
in vitro translated labeled full- length ERa and GST pull-down was performed in the
absence of ligand or in the presence of either estradiol or tamoxifen. Interaction was
detected in all three conditions, with strongest interaction detected in the presence of
estradiol (Fig. 28A , right panel), which is likely caused by the additional interaction
between ER LBD and the first LXXLL motif present within aa 612-646 of RAC3 under
this condition. Our data thus support that the aa 342-646 ofRAC3 contain another ER-
interacting surface that binds specifically to ER-
We then tried to fine map the region ofRAC3 (342-646). RAC3 (342-646) was
further divided into smaller domains and GST fusion proteins of each domain were made
and incubated with in vitro translated S labeled ER-N again. Fig. 28B shows that the N
terminal half ofRAC3 (342-646) mediates the interaction with ER- , however, this half
region binds to ER-N much more weakly than the intact RAC3(342-646), suggesting that
sequence in the C terminal half may be also involved.
D. RAC3 (342-646) selectively interacts with nuclear receptors N terminus
We then asked whether RAC3 (342-646) only interacts with ERa or it also
interacts with N-terminus of other nuclear receptors. N-terminal A/B-C regions ofER
GRa and RARa were generated and labeled with S-methionine by coupled in vitro
transcription and translation. Interestingly, we observed specific interactions of GST-
RAC3 (342-646) with N-terminus from ER and RARa, but not from GRa (Fig. 29A),
suggesting selective interactions between RAC3 and distinct receptors ' N-terminus.
While the two ends ofRAC3 (342-646) overlap with the highly conserved PAS-
and RID domain, the middle part amino acid residues 400-612 is relatively less conserved
in TIF2 and SRC- , so we investigated whether the corresponding regions in SRC-
1 and
TIF2 also directly interact with ER-N. In the GST pull down assay, GST-TIF2 (343-664)
was able to pull down the in vitro translated labeled ER- , while GST-SRC-
l(334-
656) couldn t (Fig. 29B), suggesting a selective interaction with ER-N among SRC
coactivators. Furthermore , GST-TIF2 (343-664) also interacts with N-terminus from ER
and RARa, but not that from GRa, indicating a similar selection pattern as RAC3 (342-
646).
Summary
In this chapter, we found that hMMS 19 enhances the transcriptional activity 
both ER-N mutants in which Serl18 , the phosphorylation target ofTFIIH , is changed to
either Ala or Glu. Furthermore, overexpression ofCDK7 and MATI failed to further
enhance the transcriptional activity of ER AF - 1 in the presence of hMMS 19 , suggesting
that hMMS19 enhances ER AF- 1 through a Ser118 phosphorylation-independent
pathway. However, hMMSl9 must coactivate ER AF- 1 indirectly considering the lack of
physical interaction between hMMS19 and ER-N. RAC3 may mediate the functional
interaction between hMMS19 and ER-N because it directly binds to both peptides.
Interestingly, we found a novel region in RAC3 that mediates the direct interaction with
ER-N. This region is less conserved in SRC coactivators , its counterpart in TlF2
, but not
-------
SRC- 1 also binds to ER- , suggesting a selective interaction with ER AF- 1 among SRC
coactivators.
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Chapter IV
Discussion
IV-I. FUNCTIONAL IMPLICATION OF SMRTe NUCLEAR SPECKLES
SMRTe as an organizer of a novel nuclear domain
Cell nucleus has a well-organized, yet dynamic substructure that represents a
:li1i
'"1
':I
'\1111
:!I
'IIInovel regulatory level of many molecular events(165). Remarkably, regulation of both
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transcriptional activation and repression by nuclear compartmentalization has been
reported. Using indirect immunofluorescence and transiently transfected cells , we found
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these speckles are not an artifact of protein overexpression because: 1. Endogenous
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that SMRTe distributes in discrete nuclear and cytoplasmic speckles. We believe that
SMRTe exhibits a similar nuclear speckle pattern although lacks cytoplasmic staining, ;ruc
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probably because of the weak signal; 2. In parallel experiments, cells transfected with N-
CoR in the same expression vector as SMRTe exhibits exclusive nuclear speckles ! Hllil
indicating that the cytoplasmic staining of SMR Te is unlikely caused by overexpression.
A recent report by Downes et al has demonstrated the similar dot pattern of
!1m
endogenous SMRTe , and they suggest that the presence of SMRTe in these dots/speckles
is dependent on the deacetylase activity of class II HDACs(166). However, based on the
ability ofSMRTe to recruit unliganded RAR as well as selective HDACs from the diffuse
nuclear distribution to discrete nuclear speckles, we conclude that SMRTe is the
organizer of those nuclear speckles. Our data also directly argues against that any
t ,
HDACs could be the organizer of the nuclear speckles. For example, SMRT RD2 domain
is the region that interacts with HDAC3 , but it did not show nuclear dot structure, and the
SMRT RD3 fragment that contains the HDAC4/5 interacting domain locates
constitutively in the cytoplasm, while we would expect RD3 to be in the nuclear speckles
ifHDAC4/5 was the organizer. The discrepancy between our and Downes 
et aI's results
probably arises from the fact that Downes et al 
were looking at the distribution of
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endogenous SMRTe staining in the presence of overexpressed HDAC5 , which as one
would expect, may overwhelm the endogenous SMRTe and disrupt its natural
localization. Nonetheless , consistent with our observation that the deacetylase activity of
HDACI is required for its localization in the SMRT nuclear speckles, Downes et al
found that the deacetylase activity of class II HDACs also appears necessary for their III
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distribution to the nuclear speckles.
Dynamic property of the SMRTe nuclear speckles
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First of all , SMRTe nuclear speckles have dynamic composition. Our data
revealed the in vivo association between SMRTe and unliganded receptor as well as
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HDAC1 , 3 , 4 and 5. However, biochemical analysis so far has failed to isolate a single
SMRTe complex containing so many components. Immuno-affinity chromatography
purified SMRTelN-CoR complex from nuclear extract identified only HDAC3 tightly
associated with SMRTelN-CoR. Two explanations could account for the discrepancy
between biochemical analysis and immunofluorescence result as pointed out by Downes
et al. First, some components of SMRTe complex may not be soluble , therefore will not
be present in the nuclear extract. Downes et al 
have shown that some components may be
associated with nuclear matrix and therefore will be lost during preparation of nuclear
extract. Second, the association of some components may be dynamic and not stable
enough to sustain the chromatography. Indeed, dynamic association of SMRTIN-CoR
with different subsets of corepressor complex to mediate transcriptional repression by
:,iUlli
specific repressors has been observed. Laherty et al reported that SAP30 , a component of d,fI
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the mSin3 corepressor complex was required for N-CoR-mediated repression by
antagonist-bound ER and the homeodomain protein Rpx, but not for N-CoR-mediated
repression by unliganded RAR or TR( 167). It should be noticed that our :JII!
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immunofluorescence approach tends to detect steady-state interaction because cells are HII
depending on the cell type and cell growth and differentiation. For example, class II
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fixed and most proteins are overexpressed in our experiments. It' s likely that the SMRTe
nuclear speckles are more dynamic in terms of that their composition may change
HDACs are differentially expressed in selective tissues, so we may expect different types
ofHDACs in SMRTe nuclear speckles in different cell types. Furthermore, as we have illI
inhibition ofMEF2C activity, recruitment ofHDAC4 and 5 must be tightly regulated in
III
shown that recruitment ofHDAC4 and 5 into SMRTe nuclear speckles enhanced their
order to timely activate MEF2C. Therefore, the dynamic composition of SMRTe nuclear
speckles may be an important aspect of their function to bring distinct corepressor
complex to specific transcriptional repressors.
In addition, SMRTe itself displays a dynamic subcellular distribution. Although
most transfected cells display exclusive nuclear speckles , many cells have both
cytoplasmic and nuclear speckles. We found that the N-terminal extended domain and
the RD3 of SMRTe are localized exclusively in the nucleus , suggesting that multiple
lI'
nuclear localization signals may be involved in nuclear localization of SMR Te. In
addition to nuclear localization, RD3 also appears to contribute to speckled nuclear
localization. In contrast, RD4 is responsible for speckled cytoplasmic localization, and
cSMRT appears to be lacking both nuclear and speckle localization signals. Recently,
phosphorylation by mitogen-activated protein kinases (MAPK) has been shown to cause
cytoplasmic localization of SMR T( 168), suggesting a complex signaling pathway that
regulate SMRTe localization.
Despite the obvious similarity of SMRT and N-CoR in both domain structure and
function, we found that N-CoR was detected exclusively in the nucleus. Whether this
difference in subcellular distribution reflects any significant functional difference
between SMRTe and N-CoR is not clear, however, recent data suggest that SMRT and N-
CoR may function differentially in vivo. Targeted ablation ofN-CoR gene in mouse with
wild type SMRT results in embryonic lethality, indicating that SMRT and N-CoR are not
functionally redundant proteins(33).
Biological functions of the SMRTe speckles
Possible functions of SMRTe speckles include:
A. Transcriptional revression Transcriptional repression by DNA binding
proteins involves a series of protein-protein interactions with corepressors such as SMRT
CoR and HDACs. In this study, we have confirmed the interactions of SMRTe with
HDAC1 , 3 4 and 5; however, we have found that SMRTe does not colocalize with
HDAC2 , HDAC6 and mSin3A. Interestingly, SMRTe can recruit the interacting HDACs
into discrete nuclear speckles. The colocalization ofHDAC3 , 4 and 5 with SMRTe is
consistent with previous biochemical findings. In particular, HDAC3 has been shown to
form a stable complex with SMRT and N-CoR(54 , 55 , 161), and HDAC3 can be
coprecipitated with HDAC4 and 5(162). Supports for an active role ofSMRTe in
regulating histone deacetylation come from observations that localization of HDAC 1 to
SMRTe nuclear speckles depends on the histone deacetylase activity ofHDACI.
Similarly, it was recently reported that HDAC5 and 7 mutants , when lacking HDAC
activity, as well as the deacetylase inhibitor trichostatin A and sodium butyrate , can
disrupt colocalization ofHDAC5 and 7 with the isoform of SMRTe, SMRTa(166).
Together, these data suggest an important role for SMRTe in organizing a novel nuclear
domain that may be implicated in histone deacetylation and transcriptional repression.
B. nuclear-cvtoplasmic shuttling The colocalization ofunliganded RARa with
SMRTe in the cytoplasmic and nuclear speckles confirms the reported interaction of
these two proteins in vivo. The dissociation ofRARa from the SMRTe cytoplasmic
speckles upon atRA treatment confirms the proposed theory of ligand-dependent
dissociation ofRARa from the corepressor. It appears that the presumed "SMRTe-free
RARa can be readily transported into the nucleus. However, it is not clear whether the
presence of cytoplasmic RARa is due to nuclear export or regulated import by SMRTe. It
is intriguing to note that TR also undergoes a T3-enhanced nuclear translocation(169).
Based on these findings it is reasonable to speculate that SMRTe might be responsible for
regulating nuclear-cytoplasmic shuttling ofunliganded TR and RARa. In addition, we
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found that cSMRT is primarily located in the cytoplasm, where it can block nuclear
localization of Ga14-RARa , suggesting that cellular compartmentalization may in part
contribute to the dominant negative activity of cSMRT.
The functional interaction between HDAC4 and SMRTe also suggest a new role
for SMRTe in regulating cytoplasmic-nuclear trafficking ofHDAC4 , which might be
independent of its nuclear corepressor function. In the absence of SMRTe , HDAC4 is
localized in the cytoplasm due to 14- 3 binding(157). SMRTe induces a dramatic
translocation of the cytoplasmic HDAC4 into the nucleus. In the nucleus , HDAC4 can
interact with MEF2C and inhibit its transcriptional activity that is required for muscle cell
differentiation(159 , 160). Indeed, coexpression ofSMRTe and HDAC4 abolishes
MEF2C transcriptional activity. Remarkably, it was reported recently that HDAC4 and 5
are exported from the nucleus during muscle cell differentiation via a process controlled
by calcium/calmodulin-dependent protein kinases (CaMK)(170). Thereby,
phosphorylation ofHDAC4 and 5 and/or SMRTe by CaMK might disrupt HDAC-
SMRTe interaction, leading to segregation and subsequent export ofHDAC4 and 5.
Alternatively, this signal-dependent phosphorylation event might trigger nuclear export
ofthe entire SMRTe-HDAC complex. After myoblast fusion, HDAC4 is relocated from
cytoplasm to nucleus(171). While it is clear that nuclear export ofHDAC4 and 5
accompanies MEF2C activation and muscle cell differentiation, little is known about how
HDAC4 and 5 are imported and maintained in the nucleus. Our data suggest, for the first
time , a mechanism of SMRTe-mediated nuclear import ofHDAC4 , and nuclear domain
targeting ofHDAC4 and 5. We believe that this mechanism may provide an important
piece of the puzzle for understanding signal-dependent muscle cell differentiation.
Indeed, recent findings confirm that although HDAC4 contains intrinsic nuclear export as
well as import signal , it appears that interaction with other proteins such as MEF2 is
necessary for its nuclear import( 172). Consistent with the possible role of SMRT in
muscle differentiation , N-CoR interacts with MyoD and inhibits muscle cell
differentiation(28). Therefore , it is reasonable to speculate that steroid/nuclear receptor
corepressors may enhance transcriptional repression by targeting selective HDACs to
specific nuclear domains , leading to long-term repression of muscle specific genes. We
speculate that this strategy may be prototypic for regulating the activity ofthe SMRTe-
interacting proteins, and it now poses the challenge to further define the exact mechanism
of gene regulation by the SMRTe nuclear domains.
--- --
IV-2. FUNCTIONAL RELATION BETWEEN HMMS19 AND RAC3 AND
ITS IMPLICATION FOR REGULATION ESTROGEN RECEPTORS
MMS 19 was initially identified in a yeast genetic screen for mutations that render
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cells sensitive to the alkylating agent methyl methanesulfonate (MMS) and later to UV
and DNA cross-linking agents(164). Analysis ofMMSl9 mutation in yeast suggests that
it plays a role in nucleotide excision repair and transcriptional regulation by affecting
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the yeast protein(l73 , 174). Seroz et al reported a sequence that is almost identical to our
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TFIIH activity. Recently, two groups isolated human MMS19 based on its homology to
of the protein. They found that this isoform ofhMMSl9 failed to complement the yeast
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sequence except a difference over a stretch of 39 amino acid residues in the central part
mms 19 mutant although it interacts directly with two subunits of human TFIIH complex !III
Queimado et al reported a sequence completely identical to ours and interestingly, they
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XPB and XPD , suggesting a possible conserved function in regulating TFIIH. While
found this isoform of hMMS 19 was able to rescue the yeast 
mms 19 deletion mutant
phenotype , so they concluded that this isoform of hMMS 19 is the human ortholog of
yeast MMS19. However, the functions ofMMS19 remain elusive. In this study, we
isolated the human MMS19 as a RAC3- interacting protein. We also found that hMMS19
selectively interacts with ER and functions as an AF - 1 specific transcriptional coactivator
of ER, which may help to reveal the in vivo function of hMMS 19. On the other hand
functions of bHLH - P AS domain of SRC coactivators and molecular mechanism of ER
AF - 1 are poorly understood, our findings provide an unexpected molecular link between
these two events.
Interaction of hMMS19 with RAC3 and functional significance of RAC3
bHLH-P AS domain Ii:
The bHLH-PAS domain is the most conserved region in the SRC coactivators;
::!i
however, the function of this domain is largely unkown. The isolation ofhMMS19 as a
bHLH-P AS domain-interacting protein supports our hypothesis that this domain may be tljJ
involved in protein-protein interaction during the assembly of coactivator complex.
I i
Consistent with this notion, we found that deletion ofbHLH-PAS domain in RAC3
impaired its ability to enhance transcriptional activity of ER AF - 1. Although previous
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transient transfection experiments in mammalian cells suggest that bHLH-PAS domain of
SRC coactivators is dispensable for their activity(67 , 72), recent data demonstrate that
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deletion ofbHLH-PAS domain in SRC- l reduced by 50% its enhancement ofPR activity
on chromatin templates in an in vitro system(134), confirming the importance ofbHLH-
PAS domain in coactivator function. We thus propose that at least one important function
ofbHLH-PAS domain ofRAC3 is to recruit hMm19 and maybe , a subsequent
coactivator complex. Further analysis of the hMMS19-RAC3 interactions reveals that
interaction is mediated through the P AS-A/B region. Interestingly, strong interaction
occur only in the presence of both PAS-A and PAS- , suggesting that there may be two
interacting surfaces that together stabilize the interaction between hMMS 19 and RAC3.
Since the PAS domain is highly conserved among SRC coactivators , hMMS 19 might
also interact with SRC- 1 and/or TIF2 , but this remains to be tested. However, despite the
conservation of PAS domain in different proteins , hMMS 19 does not interact with the
PAS domain of Sim, suggesting that different PAS domains may be involved with
;111:1
different interacting protein. The bHLH-PAS domains from SRC co activators may also
:::jl
function differentially, as recently reported that PASB ofN-CoAl (SRC- l), but not TIF2 ii:
or RAC3 interacts with STA T6(175).
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The RAC3-interacting surface in hMMS 19 maps to its C-terminal conserved I;:jl
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domain. Structural prediction suggests that this region contains multiple potential !I!!'
amphipathic helices , which might mediate the interaction with the PAS domain ofRAC3.
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Remarkably, during their cloning ofhMMS19 , Queimado et al identified highly ";:1'
conserved HEAT repeat domains with 4 repeats within the C terminal 170 amino acid
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residues ofhMMS19 , which overlaps with the RAC3 interacting domain. HEAT-repeat
domains have been found in a variety of cytoplasmic and nuclear proteins including
huntingtin importin and several proteins involved in transcriptional regulation. Crystal
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structure of importin reveals that a typical HEAT repeat unit consists of 30-34 amino
acid residues and forms two a-helices separated by a short loop(176). Arrays of HEAT
repeats form tandemly arranged bi-helical structures that can serve as flexible scaffolds
where other proteins assemble to form a complex(176- 178). It' s likely that these HEAT
repeats directly mediate the interaction with bHLH-PAS domain ofRAC3.
Interaction of hMMS19 with ER
.-:.
Analysis of the interactions of hMMS 19 with steroid/nuclear receptors reveals
strong binding with ERa and ER in a ligand-independent manner, while under the same
condition , almost no interaction was detected between hMMS 19 and other receptors. The
ER binding domain in hMMS 19 was mapped to the C-terminus , the same region where
acid residues or different regions in hMMS19 C-terminus , from above discussions , it'
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RAC3 binds. Although we don t know whether RAC3 and ER interact with same amino
possible that RAC3 and ER would utilize distinct HEAT repeat units ofhMMS19.
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ER-coactivator complex as these repeats do in other complexes. '!I
Therefore , hMMS 19 HEAT repeats may serve as a scaffold structure for assembling the
The hMMS 19 interacting region in ERa was mapped to the hinge region (D) (Hui
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, unpublished data). D region is less well characterized and poorly conserved among
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with the molecular chaperone heat shock protein 90 (hsp90) and therefore is capable of
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nuclear hormone receptors , however, this region has been found involved in association
mediating protein-protein interaction. Recent data also demonstrate that D region
mediates interactions of ER with coactivators L 7/SP A(29) and PGC- 1 (179). More
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interestingly, specific lysine residues in this region can be acetylated by p300 , which
leads to reduced hormone sensitivity ofERa(180). These data indicate that D region may
be an important co-regulator-binding surface for ER. Sequence alignment illustrates a
significant similarity in D region between ERa and ER but not with other
steroid/nuclear receptors , suggesting a molecular basis for the selective interaction
between hMMS 19 and ERs , although the interaction ofhMMS 19 with ER D region has
not been examined. In addition, hMMS 19 C-terminus contains several LXXLL motifs
,.:
within HEAT repeat I and whether these motifs contribute to the interaction with ER
in the presence of ligand remains to be determined.
Because hMMS 19 interacts with both ER and RAC3 and ER also interacts with
RAC3 , several possibilities may explain the relevance of these interactions. For instance
hMMS 19 may interact with ER first and in the absence of ligand. This interaction may
modulate , for example , the phosphorylation states of ER by targeting TFIIH activity to
ER or this interaction may serve to recruit RAC3 or stabilize the ligand-independent
interaction between ER AF- 1 and RAC3. Upon ligand binding, ER undergoes a
conformational change that allows the receptor to bind the LXXLL motifs of RAC3 via a
coactivator-binding pocket in the LBD. RAC3 then interacts with hMMS 19 via the N
terminal PAS domain to stabilize the complex or to signal a subsequent event in
transcription. Alternatively, since it is clear that RAC3 uses separate domains for
interactions with hMMS 19 and liganded ER, RAC3 may form a complex with hMMS 19
first, which is then recruited to the liganded receptor and the additional interaction with
ER provided by hMMS 19 would serve to stabilize the coactivator complex. Future
experiments using chromatin immunoprecipitation may be necessary to distinguish
between these possibilities by examining whether hMMS 19 and RAC3 are sequentially
or simultaneously recruited to ER target gene promoter. Nonetheless , whichever scenario
it is , Our data support that hMMS19 functions as a key factor in assembling the ER-
coactivator complex through the multiple interacting surfaces on its C-terminus, as we
have shown that the C-terminus of hMMS 19 blocked the ligand-dependent ER
transcriptional activity probably through disrupting the functional interaction between ER
and RAC3 (Fig.20C).
Interaction ofRAC3 with ER AF-
Our data confirm the previous reports that SRC coactivators interact with both
ER-N and C-terminal LBD. In the case of GRIP 1 , Webb et al has mapped the ER
interacting domain to the C terminal Glutamine-rich region and because the homology in
this region among all three SRC coactivators , they proposed that this region is a
conserved ER AF- l interacting domain(78). However, we detected only a very weak
interaction between the corresponding region in RAC3 and ER-N. Instead, aa 342-646 of
RAC3 interacts strongly with ER-N. The corresponding region ofTIF2 , aa 343-664 also
interacts significantly with ER- , which was not detected by Webb et al. Surprisingly but
consistent with sequence alignment of the corresponding regions among SRC
coactivators , which shows a stronger similarity between RAC3 and TIF2, the same region
from SRC- , aa 334-656 does not interact with ER-N in our experiment. Furthermore , the
same region ofRAC3 or TIF2 interacts with the N-terminus ofER , RARa, but not
GRa, while the corresponding region of SRC- l does not interact with the N -terminus of
any of these receptors. Interestingly, the same region ofSRC- 1 has been found to be able
to interact with progesterone receptor (PR) N-terminus(77). Therefore , it' s possible that
RAC3 (342-646) and its corresponding regions in TIF2 and SRC- l selectively interact
with a subset of receptor N-terminus , which may represent yet another level of functional
differentiation among SRC coactivators.
Amino acid 342-646 ofRAC3 contains a part of the PAS-B domain and RID of
RAC3 at the N- and C-terminal ends respectively. Although our data indicate that either
P AS-B or RID alone does not interact with ER- , removal of either N or C-terminal end
ofRAC3 342-646 almost abolished its interaction with ER-N. Secondary structure
prediction reveals that the middle region of RAC3 342-646 consists primarily of random
coils , it' s thus possible that the two ends are required for the correct folding of the middle
region , which function either alone or together with the two helical ends to form the
interacting surface for ER-
Other AF -1 specific coactivators
Two types of coactivators that specifically enhance the AF - 1 function but not AF-
2 function of ERa have been identified. The first one is the RNA coactivator for steroid
receptors , SRA(65); the second type includes p72/p68(64, 181), two members of the
RNA-binding DEAD-box protein family. Interestingly, functional interaction between
SRA and p72/p68 has been detected, suggesting they are components of a same
coactivator complex that is required for ERa AF- 1 activity.
SRA(65)
SRA was fortuitously cloned in a yeast two-hybrid screening of a human B-lymphocyte
cDNA library for PR AF - 1 interacting protein. It has multiple splicing isoforms , with one
of them expressed at significantly higher levels in the breast cancer cell lines MCF-7 and
47D. In the transient transfection assay, all the isoforms were able to specifically
enhance the transcriptional activity of steroid receptors , such as PR, GR, AR and ER, but
had no effect on TR, RAR, RXR or PP AR, suggesting that SRA is a steroid receptor
specific coactivator. Moreover, truncation ofthe AIB domain ofPR significantly reduced
coactivation by SRA, while transcription activation by PR lacking the LBD was fully
responsive to SRA , indicating that SRA mediates transcriptional activation of steroid
receptors through AF- 1. Most surprisingly, SRA is a RNA coactivator as supported by a
few lines of evidence. First, attempts to translate the SRA clones in vitro or in vivo all
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failed. Second , an affnity column containing a mouse monoclonal antibody raised
lines. Third, extensive mutagenesis of SRA, introducing multiple translational stop
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against putative SRA open reading frame failed to detect endogenous SRA in various cell
codons in all reading frames , did not affect the activity of SRA. Finally, SRA retained its Iti4ftl
ability to coactivate a reporter gene in transfection experiments in the presence of 'I!I
of the lack of sequence homology in this region among these receptors. Rather, SRA may
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cycloheximide. SRA is unlikely to directly interact with steroid receptors AF - I because
Indeed, biochemical analyses demonstrated that SRA and SRC- l were eluted in the same
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be indirectly associated with receptors as a component of a ribonucleoprotein complex.
fraction from whole cell extracts of human T-47D cells. Taken together, SRA may ;JHI
function as an adaptor molecule in a coactivator complex specific for steroid
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steroid/nuclear receptors.
p72/p68(64 , 181)
p72 and p68 are two closely related members of the DEAD-box-containing RNA
binding protein family and are presumably involved in multiple facets of cell functions. A
possible role of p68 in ER signaling was first revealed by the affinity purification of p68
from MCF- 7 cell extracts by GST fused ERa AIB- region. Both in vivo and in vitro
studies demonstrated direct interaction between p68 and ERa A/B region, which can be
potentiated by the Ser118 phosphorylation of ER. Surprisingly, p68 does not interact with
or any other steroid/nuclear receptors. Consistently, p68 overexpression enhanced
transcriptional activity of ERa through coactivating AF- , while it has no effect on
functions of ER or any other steroid/nuclear receptors. These results established p68 as
an ERa AF- l specific coactivator. On the other hand, p72 was also related to ER
signaling since it was isolated in a yeast two-hybrid screening with the activation domain
at the carboxyl terminus of AIB 1 being the bait. As expected, p68 also interacts with the
same domain of SRC co activators , whereas p72 also specifically interacts with ERa AlB
region. Moreover, p68/p72 also interacts directly with SRA through one of their
conserved DEAD-box, box viii. Furthermore , p68 elutes together with SRA-SRC-
complex in the in vitro fractionation. Interestingly, deletion of box viii in both proteins
abrogated their interaction with SRA as well as their ability to enhance the transcriptional
activation of a ER target gene in vivo , suggesting that interaction with SRA is required
for p68/p72 to function as ERa coactivator.
Role of hMMS19 in ER signaling
The physiological relevance ofhMMS19 in ER signaling is demonstrated by
overexpression of the C-terminal RS2. 1 fragment and the full-length hMMS19 , each of
which significantly affect transcriptional activity ofER in transfection assays.
Overexpression of RS2. 1 inhibits ligand-dependent transcriptional activation of an ER
reporter gene probably due to a dominant negative effect. Meanwhile, overexpression of
RS2. 1 has no effect on basal promoter activity in the absence of ligand, consistent with
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the observation that ER binds to chromatin in response to ligand. As expected, the full-
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length hMMS 19 enhances ligand-dependent transcription of the ER reporter gene
whereas the truncation mutant lacking the RAC3/ER-interacting domain has no effect on
ER activity. Intriguingly, hMMS19 strongly enhances the AF- l activity ofER in both the
absence and presence of ligand and has no effect on the activity of a separated AF-
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domain. Therefore , we suggest that hMMS 19 functions as an AF - 1 specific coactivator of
ER. Currently, only a few potential AF- 1 specific co activators were reported, such as
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p68/p72 RNA helicase(64, 181J, and the mechanism by which AF- 1 activate transcription
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and synergizes with AF-2 are largely unkown. The human MMS19 interacts with both
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ERs and RAC3 , suggesting that hMMS19 may bridge the functions of AF- 1 and AF- !!11
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Because hMMS 19 regulates AF - I activity of ER without directly interacting with :!I
ER- , it' s intriguing to ask what factor(s) mediate the function ofhMMS19. This led us
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AF- 1 activity. Furthermore, since hMMS19 interacts with the PAS domain ofRAC3 , we
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to discover that the interaction between RAC3 and hMMS 19 is necessary for enhancing
have demonstrated that the loss of PAS domain abolished the cooperation between 'I::
hMMS 19 and RAC3 to activate ER AF - I. However, how hMMS 19 functions to activate
transcriptional activity of AF- 1 as well as the full-length ER is not clear, two possibilities
exist:
A. hMMS19 mav function to facilitate hTFIIH mediated ER TJhosTJhorylation.
Biochemical and molecular biological studies in yeast suggest that yeast MMS 
function as a positive regulator of TFIIH( 164). Deletion of MMS 19 in yeast results in
general defection in transcription. Interestingly, hMMS 19 is able to complement the yeast
mms 19 deletion mutant when introduced into yeast cells, suggesting that the function of
MMS 19 in regulating TFIIH is conserved during evolution ( 173 J. Since hMMS 19 directly
interacts with two subunits of human TFIIH complex, XPD and XPB(174), it' s likely that
hMMS 19 may be able to recruit TFIIH to estrogen receptors , which leads to ER
phosphorylation and subsequent activation ofER transcriptional activity. Our data from
the phosphorylation site mutated ER-N suggest that this may not be the mechanism for
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hMMS 19 to activate at least the isolated ER AF - , although we are not sure whether this jll
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can account at least partially for how hMMSl9 activate the full-length ER. Also , our data
are obtained from transient transfection assay in 293 cells using a specific promoter-
driven reporter gene. Given the cell type and promoter context specificity ofER activity,
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'1,,we cannot rule out that the stimulated coactivation by phosphorylation may occur for
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some genes in certain cell types.
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transcrivtional machinery. From previous discussions , hMMS19 may function as a
scaffold protein to facilitate complex assembly. Furthermore, since hMMS19 selectively
interacts with ER, it may function as an adapter to recruit specific coactivator complex to
ER. Such a role is consistent with its structure propert with multiple HEAT repeats at
the C-terminus which has been identified as the RAC3- and ER- interacting domain. It is
also consistent with the fact that hMMS 19 cannot activate gene transcription by itself
when recruited to a gene promoter by a heterologous DNA binding domain fusion (our
unpub lished data). Interestingly, the idea of "adapters" or "integrators" has been
proposed to explain the function of certain members of coactivator complex, such as
SRA(65) and CBP(105), considering their ability to interact with other co activators in
addition to receptors. Therefore, the ability of certain coactivators to act as scaffold
proteins may be a common theme in the assembly of receptor-coactivator complex.
In addition to assembling coactivator complex, hMMS 19 may also be able to
recruit/stabilize general transcriptional machinery to ER in light of its association with
initiation(182 , 183). Through its inherent protein kinase and DNA helicase activity, it is
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TFIIH. As a general transcriptional factor , TFIIH plays important roles in transcription
involved in phosphorylation of the carboxyl terminal domain (CTD) of the RNA
polymerase promoter melting and promoter clearance, all of which are crucial for
effcient transcription initiation(184). Interestingly, hMMS19 binds to the two TFIIH
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subunits , XPB and XPD(174), which possess the DNA helicase activity and are
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responsible for, at least, the promoter melting. Thus it's likely that hMMS19 would
initiation. In addition, recent data demonstrate that TFIIH is also an important member of
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recruit and stabilize TFIIH at the promoter region and facilitate the transcription
the transcription reinitiation intermediate that is essential for sustained high level
transcription from a given promoter(185). Intriguingly, in vitro studies ofER activated
transcription has revealed dual functions of ER in both transcription initiation and
reinitiation(186). We suspect that by bridging TFIIH and ER, hMMS19 can be an
important factor involved in ER mediated transcription reinitiation.
Based on the above discussion, we propose a model of how hMMS19 and RAC3
cooperate to activate ER transcriptional activity (Fig. 30). In this model , in addition to the
interaction between liganded hERa LBD and RAC3 LXXLL motifs in the receptor
interacting domain, the region immediately before RID of RAC3 also contacts the hERa
AF- 1 region. Both interactions may be required to stabilize the receptor-coactivator
complex. Furthermore, the two protruding ends ofRAC3 function to recruit other factors
required for the maximum transcriptional activity, e.g. the N-terminus bHLH-PAS
domain recruits MMS 19 which also binds directly to the hinge region of ER and
therefore adds another stabilization force to the overall complex; while the C-terminus is
necessary to recruit CBP/PCAF complex which also directly binds the receptor. Both
complexes at the N or C-terminus may synergistically activate ER transcriptional activity
in multiple ways: 1. through phosphorylating ER by kinase activity from TFIIH-
hMMS 19 complex; 2. through histone acetylation by the HAT activity from RAC3 or
CBP/p300 or pCAF; 3. through recruiting the basal transcriptional machinery due to the
recruitment of TFIIH by hMMS 19 and recruitment of TFIIB by CBP. This model
predicts a central role ofRAC3 and hMMSl9 in assembling the coactivator complex
111
although we don t know if they interact with ER simultaneously or sequentially, future
'I'
experiments are necessary to clarify this.
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Fig. 1 Schematic representation of a nuclear hormone receptor domain structure. A
typical nuclear receptor consists of A, B , C , D , E and F six regions. The variable N-
Ii,
terminal region A/B contains the ligand-independent transcriptional activativation
domain AF- 1. C is the conserved DNA binding domain, followed by the hinge region D.
E/F contains the ligand binding domain as well as the ligand-dependent transcriptional
activation domain AF-2. (Adapted from Aranda A. and Pascual A(3J.
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Fig. 2 Current model of transcriptional regulation by nuclear hormone receptors:
the role of coactivators and corepressors. In the absence of ligand, corepressors
SMRTIN-CoR wil recruit a corepressors complex containing HDAC activity to the
receptors and actively repress transcription through deacetylating histones or some other
protein. Ligand binding induces the release of corepressors and recruitment of coactivator
complex containing HAT activity, resulting in transcriptional activation. Both
corepressor and coactivator complex may also affect transcription through functional
interaction with basal transcriptional machinery (Adapted from Glass CK and Rosenfeld
Genes Dev. (2000) Vol 14(2), 121- 141).
101
hN-COR 1 ,
. -
R01 SA NT R02 R03r- /' 2440101 102
hSMRTe 2507
2499
1.1109HA
SNC-SANT HA165 665 1013 2507
RD3 HA 1487
RD4 HA 1193
1487 
cSMRT 2507
1994 .. 
Fig. 3 Schematic representation of the N-CoR/SMRTe domain structure as well as
SMRT, cSMRT, and hemagglutinin (HA)-tagged deletion constructs used in this
study. RDl- transcriptional repression domains; IDI- nuclear receptor interacting
domains; LXXLL- like motif; SNC SMRTelN- CoR conserved domain; SANT
SWI3/ADA21N-CoR/TFIIIB domains; Q, poly- glutamine repeat; EK/ER alternating
acidic/basic regions;SG , alternating serine/glycine region. The numerical numbers are
amino acid residues based on GenBankTM accession number AF125672.
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Fig. 4 Schematic diagram of the domain structures of full-length human RAC3,
TIF2 , and SRC-l. The starting and ending residues of indicated domains are shown. The
RAR-binding and p300-binding domains defined in mSRC- 1 are also indicated. The
numbers at the right are the length of individual proteins and the percentage 
similarity.
The pairwise similarities were calculated to be 65% between RAC3 and TIF2
, 64%
between TIF2 and SRC1 , and 59% between RAC3 and SRC1 (Adapted from Li et al
Proc Natl Acad Sci USA (1997) Vol 94 , 8479-8484).
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Fig. 5 Subcellular localization of full-length SMRTe and N-CoR. HeLa cells were
transiently transfected with SMRTe or HA-tagged N-CoR Immunohistochemistry was
conducted with mouse anti- SMRTe monoclonal antibodies (a-c), or mouse anti-
monoclonal antibodies (d). The mouse primary antibodies were detected by goat anti-
mouse rhodamine-coupled secondary antibody (red). The endogenous SMRTe speckle
staining is also shown (c).
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Fig. 6 Subcellular localization of full-length SMRTe and SMRTe fragments. HeLa
cells were transiently transfected with SMRTe, SMRT , cSMRT, or HA-tagged deletion
mutants shown in lower right (RD3=SRDl , RD4=SRD2).
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Fig. 7 Co-staining of SMRTe and SC35 or Daxx. HeLa cells were transiently
transfected with SMRTe and stained with rabbit anti-SMRTe polyclonal antibodies and
mouse anti- SC35 antibodies (a-c), or mouse anti- SMRTe monoclonal antibodies (d-./ and
rabbit anti-Daxx antibodies. The rabbit primary antibodies were detected by fluorescein-
coupled goat anti-rabbit secondary antibodies (green). The mouse primary antibodies
were detected by goat anti-mouse rhodamine-coupled secondary antibody (red). 
colocalization was observed in the double labeling of SMRTe and the SC35- labeled
splicing speckle (c), or SMRTe and the Daxx- labeled promyelocyte nuclear domain 
(j.
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Fig. 8 Ligand-independent colocalization of RAR with SMRTe. SMRTe sequesters
RAR in the cytoplasmic speckles in the absence (-) (a-c), but not the presence (+) (d-j, 
atRA. SMRTe and HA-tagged hRR were double-labeled with rabbit anti-SMRTe and
mouse anti-HA antibodies , followed by fluorescein(green) or rhodamine (red)-coupled
secondary antibodies, respectively. HeLa cells were transiently transfected with pCMX-
hSMRTe and pCMX-hRAR followed by 10- M atRA treatment for 24 h before
immunostaining.
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Fig. 9 cSMRT sequesters GaI4-RAR in the cytoplasm in an RA-sensitive manner.
pCMX-cSMRT and pCMX-GaI4-RAR were cotransfected in HeLa cells. Ga14-RAR was
detected by mouse anti- Gal4 DNA binding domain monoclonal antibodies (red) and the
cSMRT with rabbit anti- SMRTe polyclonal antibodies (green). (a-c) show that in the
absence of atRA, Gal-RAR is sequestered in the cytoplasm; (d-f) show that atRA
treatment relocate Gal-RAR to the nucleus; 
(g-
i) show that as a control , cSMRT cannot
sequester Gal in the cytoplasm.
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Fig. 10 SMRTe colocalizes with PLZF and ETO. HeLa cells were transiently
transfected with SMRTe and PLZF or ETO-Flag and stained with rabbit anti-SMRTe
polyclonal antibodies and mouse anti- PLZF antibodies (a-c), or mouse anti-Flag
monoclonal antibodies (d-f). The rabbit primary antibodies were detected by fluorescein-
coupled goat anti-rabbit secondary antibodies (green). The mouse primary antibodies
were detected by goat anti-mouse rhodamine-coupled secondary antibody (red).
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Fig. 11 SMRTe recruits HDACI and HDAC3 into nuclear speckles but not HDAC2
or mSin3A. SMRTe was transfected into HeLa cells together with HA-tagged HDAC2
HDAC3 , or FLAG-tagged HDAC1 or mSin3A and double-labeled by rabbit anti-SMRTe
and mouse anti-HA or anti-FLAG antibodies. Panels a, e, i and show transfections of
each HDAC or mSin3A alone. We found that, without cotransfection with SMRTe
HDAC1 , 2 , and 3 were diffusely distributed in the nucleoplasm , e, i), whereas mSin3A
alone displayed a fine speckled pattern (m). Cotransfection with SMRTe recruits HDACI
(b-d) and HDAC3 (j-I), but not HDAC2 ifh) or mSin3A (n-
p) 
into nuclear speckles.
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Fig. 12 Histone deacetylase activity is required for localization of HDACI to SMRTe
nuclear speckles. SMRTe and each HDAC1 mutant were cotransfected and analyzed as
in Fig. 11. The partially active H141A mutant colocalized well with SMRTe (a-c),
whereas the H199A (d-j and D176N 
(g-
i) mutants , which are void of deacetylase
activity, did not show colocalization with SMRTe.
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Fig. 13A Association of SMRTe with class II HDACs. 
Class II HDACs , HDAC4, 5 , or
6 were transfected alone , e , i) or together with SMRTe. In the absence of SMRTe
HDAC4 is located primarily in the cytoplasm 
(a). Coexpression with SMRTe translocates
HDAC4 from cytoplasm into the nucleus 
(b-d). SMRTe also recruits HDAC5 from
diffuse nucleoplasmic staining (e) into nuclear speckles (fh). 
SMRTe did not recruit the
cytoplasmic HDAC6 into the nucleus (i-I).
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Fig. 13B Quantitation of the relative localization of HDAC4, HDAC5, and HDAC6
in the absence (-) or presence (+) of SMRTe coexpression. The localizations of each
HDAC shown in were quantitated by recording transfected cells with specific
localization patterns. Cyto indicates cells with predominant cytoplasmic staining;
Cyto/Nu indicates cells with both cytoplasmic and nuclear staining; Nu indicates cells
with predominant nuclear staining. The nuclear staining with diffused or speckled
localization is also indicated for HDACS. The nuclear staining ofHDAC4 in the presence
of SMRTe is primarily in nuclear speckles. About 2S0 to 3S0 transfected cells were
recorded in each experiment.
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Fig. 14 SMRTe enhances HDAC-mediated transcriptional inhibition on MEF2C. 
HEK293T cells were transfected with MEF2C (0.2 !Jg/well) and a MEF2C-dependent
luciferase reporter (0.4 !Jg/well) together with each indicated HDAC or empty vector (0.2
!Jg/well). Note that only HDAC4 and 5 show significant inhibition on MEF2C
transcriptional activation. coexpression of SMRTe and HDAC4 and 5 synergistically
inhibits MEF2C-mediated transcriptional activation. Transfection was conducted as in 
i1i
with the addition ofSMRTe where indicated at a concentration of 0.2 !Jg/well. SMRTe
alone has little effect on MEF2C activity, whereas cotransfection ofSMRTe and HDAC4
or HDAC5 synergistically inhibits MEF2C activation by 20-fold
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Fig. 15 Interactions of RS2. 1 with RAC3 in vivo.
yeast two-hybrid interaction ofRS2. 1 with RAC3-N. RS2. 1 is expressed in the pACT2
vector as a Ga14 activation domain fusion , whereas the baits are expressed in pGBT
vector as Ga14 DNA binding domain fusion. Vector alone without insert is marked as "
Sim-N contains the bHLH-PAS domain of the Sim.
B, yeast two-hybrid interaction of RS2. 1 with various regions of the RAC3 N-terminal
domains , conducted as described in 
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Fig. 16 Multiple sequence alignment of human MMS19 with related sequences of
different species. Multiple sequences were aligned by ClustalW and plotted using
ESPript program.
background. Highly conserved residues are also boxed and displayed in red. hMMS 19
and hMMS 19mt are indicated as well as the starting residue encoded by the yeast two-
Consensus amino acids are boxed and displayed in white against red
' '
hybrid clone RS2. 1. Amino acid sequences of related proteins in C.elegans, A. thaliana
and S.cerevisiae are derived from the Genbank accession numbers: T33176 BAB11076
and NP 012138, respectively. Amino acid sequence of the related protein in 
melanogaster is predicted by GENSCAN from Drosophila genomic sequence AE003603
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Fig. 17 Ubiquitous expression of hMMS19 in human tissues and cancer cells. Total
mRNA samples from various human tissues and cancer cell lines were probed by a 32
labeled random-primed DNA corresponding to the NsiI/BglII restricted 1.5kb fragment
from the cloned hMMS 19. A unique band of hMMS 19 transcript in the size of about 4
kilobase was detected in all the samples examined; Actin is shown as a control.
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Fig. 18 Nuclear localization of hMMSI9. 
Indirect immunofluorescence analysis of
HeLa cells transfected with HA-hMMS19 and detected by an anti-HA monoclonal
antibody followed by a rhodamine-coupled secondary antibody. The right panel shows
nuclear staining with 4' , 6-diamidino- phenyl- indole (DAPl) of the same cells.
118
l f
,""
"- cf "- cf
oS (!
KDa
175 -
83 -
62 -
47,5 -
32,
25 -
35s. hMMS1SC hMMS19-mt hMMS19
:1 a: a: ct 
i; (
:) (
u 0 0 u
.. .. .. .. 
CC CC CC CC 
0. cf cf cf cf cf 
oS (! (! 
(! (! (!
KDa
175-
B3- 
,,- ..- '--
35S-hMms19
62-
Fig. 19 Interactions of hMMSI9 with GST-RAC3-N in GST pull-down assay.
A. The hMMSl9 C-terminus (RS2. 1), hMMS19-mt and full- length hMMS19 were
translated in reticulocyte lysate and labeled with S-methionine and incubated with
glutathione agarose beads coupled with GST or GST-RAC3- , bound proteins were
eluted and analyzed by SDS-PAGE and autoradiography. While hMMS19C and
hMMS19 can be pulled down, very few amount ofhMMS19-mt was pulled down.
B. interaction of full-length hMMS19 with RAC3 in GST pull-down assay, conducted as
described in A. except that different GST -RAC3 fusion proteins are used in this
experiment. Only GST-RAC3-PASAB and the bait can pull down significant amount
hMMS19.
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Fig. 20 The RS2. 1 fragment modulates transcriptional activity of ER. RS2.
inhibited ligand- induced ER transcriptional activity, while it had no effect on
transcriptional activity of hRAR or hTR on RARE-tk-Luc or TRE-tk-Luc reporter
respectively. B. dose-dependent inhibition of ligand-induced transcriptional activity of
ERs by RS2. 1. Increasing concentrations ofRS2. 1 (- 0 ng; +, 100 ng; ++, 200 ng; +++
400 ng) were transfected into HEK293 cells together with 20 ng of ER and 0. g of the
ERE-E1A-Luc reporter. After transfection, cells were treated with solvent or 25 pM of
, and relative luciferase activity was determined.
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Fig. 21 The human MMS19 interacts with estrogen receptors. interaction of full-
length hER with RS2. 1 in GST pull-down assay in the absence or presence of 1 /-M 17-
estradiol (E2) or 1 /-M 4- dihydroxytamoxifen (ORT). GST-RS2. 1 pulls down a
significant amount of ER in a ligand- independent manner. interactions of ER
hRAR, or hTR with GST-RS2.1 in GST pull-down assay conducted as described earlier.
, Coomassie Blue staining ofGST and GST-RS2. 1 protein used in the GST pull-down
experiments.
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Fig. 22 The full-length hMMS19, but not hMMS19-mt, consistently enhances ER-
mediated transcriptional activation. 200 ng of hMMS 19 or hMMS 19-mt were
transfected into HEK293 cells together with 20 ng of ER and 0.5 Ilg of the ERE-E1A-
Luc reporter. Relative luciferase activity was determined as described before.
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Fig. 23 The human MMS19 is an AF- l-specific transcriptional coactivator of ER.
The hMMSl9 enhances transcriptional activation by the ER AF- 1 domain in the absence
or presence of E2. The ER AF- l contains the N-terminal A/B region and the DNA
binding domain of ER. The ER AF-2 contains the DNA binding domain and the D-
region. Note that cotransfection of hMMS 19 significantly enhances transcriptional
activation by ER AF- 1 but has no effect on ER AF-
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Fig. 24 ER N S118 mutants can stil be activated by hMMS19. 293 cells were
transiently transfected with ERE-E1a-Luc together with wild type ER-N or mutant ER-
where Ser118 was changed to either Ala or Glu. Both mutants are still transcriptionally
active and the activity can still be enhanced by hMMS 19 cotransfection.
124
f/ 80
(L 60
(3 40
.. 20
hMMS19
MAT1 +CDK7
Fig. 25 Coexpression of CDK7 and MATt failed to enhance the activation of
hMMSt9 on ER N. 293 cells were transiently transfected with ERE-E1a-Luc together
with ER- , cotransfection of hMMS 19 stimulated ER-N mediated transcriptional
activation, however, further expression of CDK7 and MATI together, two TFIIH
subunits that are capable of phosphorylating Serl18 , have no appreciable effect on ER-
transcriptional activity.
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Fig. 26 Cooperative effect of hMMSl9 and RAC3 on ER and ER AFl, but not AF2.
293 cells were transiently transfected with ERE-EI a-Luc and hERa or the separate ER-
or ER- , containing AF- l or AF-2 respectively. Cells were treated with or without 
estradiol to examine the ligand induced activity. Effect ofRAC3 , hMMS19 or combined
RAC3 and hMMS 19 were tested on the transcriptional activity of each activator.
Cooperative enhancement by RAC3 and hMMS 19 on the transcriptional activity
mediated by hERa or ER-N was observed.
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Fig. 27 RAC3 N-terminus required for its activation of ER-N. 293 cells were
transiently transfected with ERE-E1a-Luc and the hERa N-terminus. While
cotransfection of RAC3 enhanced the transcriptional activity of hERa N, the truncation
mutant RAC3dN failed to do so. RAC3dN also lost the ability to further enchance the
activity when co-transfected with hMMS 19.
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Fig. 28 RAC3 (342-646) directly binds ER N- terminus. A. ER N interacting domain
mapping on RAC3. GST fused various domains , which, when combined together covered
the full-length RAC3 , were incubated with in vitro translated S labeled ER-N. A strong
interaction with the probe was observed for GST -RAC3 (342-646) only. Right panel
shows that RAC3(342-646) binds to full length hERa also. The interaction with full-
length hERa is independent on the presence ofligand. B. Further mapping ofRAC3(342-
646). RAC3(342-646) was further divided into small domains and GST fusion propteins
of each domain were made and incubated with in vitro translated S labeled ER-
again. The interacting domain was mapped to the N terminal half ofRAC3(342-646).
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Fig. 29A. RAC3(342-646) also binds RAR. ERJ3, but not GR. Interactions between
RAC3(342-646) and various nuclear receptor N terminus were examined by GST pull
down assay. N terminus of rERf3, hRARa and hGRa were in vitro translated and labeled
with S and then incubated with GST -RAC3(342-646). Selective interactions between
GST -RAC3(342-646) and rERf3 or hRRa were observed, while no interaction with
hGRa can be detected.
B. TIF2 , but not SRCI corresponding region binds to ERs and RAR. The ability of
SRCI and TIF2 counterparts ofRAC3(342-646) to interact with N terminus of various
nuclear receptors were examined by GST pull down assay. GST-SRC1(334-656) failed to
interact with any N terminus of those receptors , while GST- TIF2(343-664) also binds
that of ERs as well as RAR, but not GR.
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Fig. 30 A Model of how RAC3 activates ER. In addition to the interaction between
liganded hERa ligand binding domain and RAC3 LXXLL motifs in the recetpor
interacting domain, the region immediately before RID ofRAC3 also contacts the hERa
AF- 1 region. Both interactions may be required to stabilize the receptor-coactivator
complex. Furher, the two protruding ends ofRAC3 may fuction to recruit other factors
required for the maximum transcriptional activity, e.g. the N-terminus bHLH-P AS
domain recruits MMS 19 which also binds directly to the hinge region of ER and
therefore adds another stabilization force to the overall complex; while the C-terminus is
necessary to recruit CBP/PCAF complex which also directly binds the receptor. Both
complexes at the Nor C-terminus may synergistically function to recruit the basal
transcriptional machinery.
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CHAPTER VII
REPRINTS
1.) Wu X , Li H , Park EJ and Chen JD. J BioI Chern. 2001 Jun 29;276(26):24177-85.
SMRTE inhibits MEF2C transcriptional activation by targeting HDAC4 and 5 to nuclear
domains.
) Wu X, Li H and Chen JD. J BioI Chem. 2001 Jun 29;276(26):23962-
The human homologue of the yeast DNA repair and TFIIH regulator MMS19 is an AF-
specific coactivator of estrogen receptor.
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The silencing mediator for retinoic acid and thyroid
hormone receptors (SMRT) mediates transcriptional re-
pression by recruting histone deacetylases 
(HDACs) to
the DNA-bound nuclear receptor complex. The fu-
length
SMRT (SMRTe) contais an N-termnal sequence that 
highly conserved to the nuclear receptor corepressor N-
CoR. To date, little is known about the activity and 
fuc-
tion of the fu-length SMRTe protein, despite extnsive
studies on separated receptor interaction and transcrip-
tional repression domains. Here we show that SMRTeinbits MEF2C transcriptional activation by targeting
selective HDACs to unque subnuclear domais. Indirect
immunofluorescence studies with anti-SMRTe antibody
reveal discrete cytoplasmic and nuclear speckles, which
contain RAa in an RA-sensitive maner. Formation 
the SMRTe nuclear speckles results in recrutment of 
sev-
eral class I and class II HDACs to these subnuclear do-
mais in a process depending on HDAC enzyatic activ-
ity. Intrgugly, although HDAC4 is located priarly in
the cytoplasm, coexpression of SMRTe dramatically
translocates HDAC4 from the cytoplasm into the nucleus,
where HDAC4 prevents MEF2C from activating muscle
dierentiation. SMRTe also translocates HDAC5 from dif-
fusive nucleoplasm into discrete nuclear domains. Ac-
cordigly, SMRTe synergizes with HDAC4 and 5 to inbit
MEF2C transactivation of target promot , suggesting
that nuclear domai targeting of HDAC4I5 may be impor-
tant in preventing muscle cell differentiation. These re-
sults highlght an unexpected new fuction of the nuclear
receptor corepressor SMRTe for its role in reguating cel-
lular trafcking of nuclear receptor and selective HDACs
that may play an important role in reguation of cell
growth and differentiation.
The steroid/nuclear hormone receptors constitute an impor-
tant superfamily oftranscriptional regulators that control gene
expression both in the absence and presence of hormones. The
transcriptional activity of these receptors is regulated by inter-
actions with co activators and corepressors, depending on the
presence or absence of ligands , respectively. In the absence of
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ligand, retinoic acid (RA)l and thyroid hormone receptors
(RAa and TRJ3 interact with the corepressors SMRT and
CoR (1 2). Upon ligand binding, corepressors dissociate from
the liganded receptors due to a conformational change in the
receptors. The liganded receptors bind the co activators through
a hydrophobic pocket on the surface of the receptor
s ligand-
binding domain (3). Prominent among the coactivators is the
steroid receptor coactivator (SRC) family that includes SRC-
TIF2/GRIP1 , and RAC3/ACTRlAIB1 (3). It is believed that the
exchange of corepressor with coactivator in response to ligand
underlies a basic principle of transcriptional regulation by ste-
roid/nuclear hormone receptors.
SMRT and N-CoR are two distinct, but highly related pro-
teins that share similar domain structure and function (1 , 2).
We have previously reported the cloning of a full-length SMRT,
designated SMRTe (SMRT-extended). SMRTe contains an N-
terminal sequence that is highly related to N-CoR, including a
SANT domain (4). Currently, the biological function of this
terminal domain remains unknown. cSMRT represents a
dominant negative mutant that contains only the receptor-
interacting domain (5), similar to the dominant negative N-
CoRi (6). SMRT and N-CoR also interact with other transcrip-
tional regulators , such as Pit-1 (7), CBF-lIBP-JK (8), and
PLZF (9). Furthermore, SMRT and N-CoR have been shown to
interact with mSin3A and several members of histone deacety-
lase (HDAC) family (10-14). HDACs can be subdivided into
two classes based on size and sequence considerations (15). The
first class (D contains HDAC1 , 2 , and 3, which are smaller in
size and related in sequence to the yeast 
RPD3. The second
class (II) contains HDAC4 , 5 , 6 , and 7 , which are larger in size
and related in sequence to the yeast HDAl. HDAC catalyzes
removal of acetyl-groups from hyperacetylated histone
, and
this de acetylation process leads to modification of nucleosome
structure, resulting in transcriptional silencing (16).
To understand the activity and function of the full-length
SMRTe , we have analyzed the expression , cellular distribution
and in vivo association of SMRTe with 
RAa and HDACs.
SMRTe is differentially expressed in cancer cells and appears
to be down-regulated by all-trans-RA. Indirect immunofluores-
cence analysis reveals localization of SMRTe in discrete cyto-
plasmic and nuclear speckles. In contrast, the dominant nega-
tive cSMRT is diffusely located in the cytoplasm, partly
explaining its dominant negative activity. Double-label immu-
nofluorescence reveals in vivo 
association of SMRTe with 
RAa
1 The abbreviations used are: RA, retinoic acid; RA, retinoic acid
receptor; TR, thyroid hormone receptor; SMRT , silencing mediator for
retinoid and thyroid hormone receptors; SMRTe, SMRT-extended;
HDAC , histone deacetylase; MEF2 , myocyte enhancer factor 2; SNC,
SMRTe/N-CoR conserved domain; HA, hemagglutinin; kb
, kilobase(s);
aa, amino acid(s); RD3 , 4 , repression domains 3 and 4; atRA, all-
trans
RA; SANT , SWI3/ADA2/N-CoRtFIIB domain; cSMRT, c-terminal do-
main of SMRT.
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and HDACl, 3, 4, and 5. We show that the association of
SMRTe with RAa is atRA-sensitive, whereas the association
with HDACI depends on HDAC enzymatic activity. Remark-
ably, SMRTe also mediates nuclear translocation of HDAC4
from the cytoplasm and nuclear domain targeting of both
HDAC4 and HDAC5 to SMRTe nuclear speckles. Cotransfec-
tion experiments demonstrate a synergistic inhibition by
SMRTe and HDAC4/5 on MEF2C-mediated transcriptional ac-
tivation. Therefore, these data suggest a new function of
SMRTe in cellular traffcking and a potentially novel mecha-
nism for SMRTe-mediated transcriptional inhibition.
MATERIAS AND METHODS
Plasmids and Antibodies-The full-length human SMRTe was con-
structed by assembling the N-terminal-extended sequence (4) with the
original SMRT (1) into the pCMX vector, creating pCMX-SMRTe. The
class I and class II HDACs and the HDAC mutants (17), the MEF2C
and MEF2Cx3-luciferase reporter (18), the rabbit (4) mouse anti-
SMRTe (GeneTex, San Antonio , TX), and the mouse anti-SC35 and the
rabbit anti-Dax antibodies (19) have been described before. The anti-
FLAG M2 and the anti-HA antibodies were purchased from Kodak
and/or Santa Cruz Biotechnology. The fluorescein- or rhodamine-cou-
pled goat secondary antibodies were purchased from Rockland and
Chemicon.
In Vitro Transcription/Translation-The in vitro transcription!
translation reactions were conducted by the T7-Quick reticulocyte ly-
sate system (Promega, Inc.
). 
CoR SMRT, SMRTe , and cSMRT are all
in the pCMX vector under the regulation of T7 and cytomegalovirus
promoters. The reactions were incubated at 30 oC for 90 min according
to the manufacturer s instruction.
Northern and Western Blots- Western blot was conducted using
the ECL kit (Amersham Pharmacia Biotech) according to the manufac-
turer s instructions. The anti-SMRTe monoclonal antibodies were pro-
vided by GeneTex (San Antonio, TX). Total cell lysate were prepared by
lysing cells directly in SDS-sample buffer and analyzed on 6% SDS-
polyacrylamide gel. Afer blotting and incubation with primar and
secondar antibodies, the blot was developed by ECL reagents and
subjected to autoradiography. For Northern blotting, the cancer cell
Northern blot was purchased from CLONTECH. The blot was hybrid-
ized with indicated 32 labeled DNA probes that were generated by
random priming reactions (Ambion, Inc.
Indirect ImmunofZuorescence-HeLa cells were seeded on cover-
glasses in 12-well plates 1 day prior to transfection. Twelve hours after
transfection, cells were fied in a methanol:acetic acid (1:1 , v/v) mixture
and processed for indirect immunofluorescence staining as previously
described (19). Cell nuclei were costained with the DNA dye DAPI
(4' , diamidino- phenylindole dihydrochloride hydrate, Sigma Chem-
ical Co. ). Coverglasses were mounted with a ProLong Antifade kit(Molecular Probes). Standard epifluorescence microscopy was per-
formed on an Olympus 1X-70 deconvolution microscope equipped with a
back-iluminated cool charge-coupled device camera (Princeton Scien-
tific Instruments), and the image was processed using the MetaMorph
software (University Imaging Corp.
Cell Culture and Transient Transfection-HeLa and 293T cells were
maintained in Dulbecco s modified Eagle s medium supplemented with
10% fetal bovine serum (Life Technologies
, Inc. ). One day prior to
transfection, cells were seeded in 12-well plates , and transient trans-
fection was performed using a standard calcium phosphate precipita-
tion method. Transfection was continued for 12 h, and the precipitates
were removed by washing with phosphate-buffered saline. Afer trans-
fection, cells were grown for 38-40 h and analyzed for luciferase and
l3-galactosidase activities as previously described (20). The luciferase
activity was determined with an MLX plate luminometer (Dynex) and
normalized with the cotransfected l3-galactosidase activity.
RESULTS
Expression of SMRTe in Cancer Cells and Its Regulation by
RA-The full-length human and mouse SMRTe (4) contains an
terminal sequence of 1012 amino acids (aa) that is extended
from the original SMRT sequence (1) (Fig. JA). This full-length
human SMRTe was assembled and transcribed/translated 
vitro and the labeled product was analyzed by SDS-poly-
acrylamide gel electrophoresis in relation to N-CoR, SMRT
and cSMRT (Fig. IB). The largest polypeptide migrated as a
270-kDa protein (lane 3), which is very similar in size to N-CoR
and is much larger than SMRT and cSMRT. Transfection of
SMRTe in mammalian cells also produced similar protein as
detected by Western blotting using anti-SMRTe antibody
(lanes 6 and 7). Similarly, the endogenous SMRTe was readily
detectable in cell lysate prepared from HeLa, MCF7 , T47D , and
CV-l cells , as well as from HBLI00, 293T, and SWI-3 cells
albeit at slightly lower levels (Fig. lC). Furthermore , we found
that SMRTe expression appeared to be down-regulated by all-
trans-RA in NB4leukemic cells (Fig. il). These data indicate
that SMRTe encodes a full-length protein of 270 kDa that is
differentially expressed in cancer cells and negatively regu-
lated by RA.
To analyze the SMRTe mRNA levels in cancer cells, we con-
ducted Northern blotting of various cancer cells with three dif-
ferent regions of SMRTe as probes (Fig. lE). All probes detected
a 9. kb band. Ths SMRTe message was expressed most abun-
dantly in HeLa and SW480 cells, consistent with the Western
blot data. Interestingly, the SMRTe probe covering the
tennal conserved SNC-SANT domai detected an additional
band of 7.5 kb. Ths 7. kb message was also expressed abun-
dantly in HeLa and SW480 cells but was absent in MOLT-4 and
A549 cells. By contrast CoR was expressed as an 8. kb mes-
sage that migrated between these two SMRTe bands. CoR
expression was also most abundant in HeLa and SW 480 cells
suggesting coordiated reguation of SMRTe and CoR expres-
sion is possible.
Subcellular Localizations of Full- length SMRTe and SMRTe
Fragments-To help understand the function of SMRTe, we
analyzed the subcellular localizations of full-length SMRTe
and several SMRTe fragments in mammalian cells by indirect
immunofluorescence (Fig. 2). We found that a majority of full-
length SMRTe-transfected cells (80-90%) displayed exclusive
nuclear speckle staining (Fig. 2a), whereas about 10-20% of
transfected cells displayed overall speckle pattern in both cy-
toplasmic and nuclear compartments (Fig. 
, a). Similarly,
immunostaining of endogenous SMRTe also revealed nuclear
speckle pattern, suggesting that such nuclear speckles are not
an artifact of protein overexpression. The existence of endoge-
nous cytoplasmic SMRTe is not conclusive due to high back-
ground of cytoplasmic staining with the available antibodies.
We then wished to determine the domain that determines
SMRTe speckle localization by analyzing a series of SMRTe
deletion mutants (Fig. JA). The N-terminal extended domain
between amino acids 1 and 1109 was located exclusively in the
nucleus in a diffse pattern, suggesting that this domain con-
tains nuclear localization signal but lacks the speckle signal.
Interestingly, the highly conserved SNC-SANT domain was
located mainly in the cytoplasm, indicating that nuclear local-
ization signal is located outside of the SNC-SANT region. The
original SMRT protein without the N-terminal extended do-
main was distributed mainly in nuclear speckles in a manner
that is similar to SMRTe and consistent with an intact core-
pressor function. Furthermore, the repression domain 3 (RD3
formally SRDI (21)) was located exclusively in the nucleus with
speckles , indicating that this domain contains a separated nu-
clear localization signal and a potential speckle localization
signal. In contrast, the RD4 domain (formally SRD2 (21)) was
located exclusively in the cytoplasm with a pronounced speckle
pattern, suggesting that the RD4 contains a cytoplasmic
speckle signal. Interestingly, the nuclear receptor interacting
domain alone (cSMRT) displayed a diffuse, mostly cytoplasmic
staining, indicating that it lacks a nuclear localization signal.
The speckle localization pattern of SMRTe prompted us to
investigate whether the SMRTe nuclear speckles correspond to
any known nuclear structures. We found no evidence of colo-
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FIG. 1. Expression of SMRTe in vitro and in vivo. A schematic representation of SMRTe
, SMRT, cSMRT, and hemagglutinin (HA)-tagged
deletion constructs used in this study. RDl- transcriptional repression domains; 
IDl- nuclear receptor interacting domains; IX, LXL-like
motif; SNC SMRTe/N-CoR conserved domain; SANT SWI3/ADA2/N-CoRlFIIB domains; Q, poly-
glutamin repeat; EK/ ER alternating
acidic/asic regions; alternating serie/glycine region. 
The numerical numbers are amino acid residues based on GenBankr: accession number
AF125672. expression of SMRTe in vitro 
and in vivo. Lanes 4 show an autoradiography of the ( SJmethionine labeled in vitro translated
proteins. Lanes 7 show a Western blot of 293T cells transfected with empty vector or pC:M-
SMRTe at two different concentrations , followed by
Western blot analysis with SMRTe monoclonal antibody. C, Western blot analysis of endogenous SMRTe in indicated mammalian 
culture cells.
Equal amounts of lysate were loaded in each well as determined by Coomassie Blue staining (not shown). 
down-reguation of SMRTe protein
levels by RA in NB4 acute promyelocytic leukemic cells. NB4 cells were treated with 1 
JLM all-trans- and cell lysate was prepared and analyzed
by Western blot. Coomassie Blue staining indicates equal protein loading. 
cancer cell Northern blot for SMRTe and N-CoR. Northern blot was
conducted by sequential hybridization with the SMRTe N terminus probe (aa 1-165), the cSMRT probe
, the SNC-SANT domain probe, the human
CoR probe , and the /3-actin probe as control.
calization between SMRTe and the splicing factor SC35 , nor
did SMRTe colocalize with the promyelocyte oncogenic domains
revealed by anti-Dax staining (19). SMRTe staining was also
not observed in the nucleoli, condensed chromatin, or centro-
meres (data not shown), suggesting that these SMRTe nuclear
speckles represent a novel class of nuclear structures. These
data also suggest that SMRTe contains multiple sequences for
regulating its precise subcellular localization.
Association of SMRTe with RAa in Vivo-To provide evi-
dence for a role of SMRTe in RA signaling, we examined the
association of SMRTe with RAa in vivo in the absence or
presence of RA (Fig. SA). As previously reported RAa alone
was distributed diffusely in nucleoplasm (data not shown).
Interestingly, coexpression with SMRTe redistributed RAa
into both the cytoplasmic and nuclear speckles in the absence
of ligand (a-c), demonstrating an in vivo interaction between
C.. l1 l n+"h I:M"R'T,. "'nilnnli2"anded RAa. Interestingly, atRA
treatment abolished this colocalization, leading to exclusive
nuclear staining of RAa without affecting the SMRTe local-
ization (d-f). This observation is consistent with previous 
vitro evidence that atRA induces dissociation of SMRT from the
receptor (1). As a control, no cytoplasmic colocalization between
SMRTe and RXa was observed (data not shown), indicating
specificity of this assay.
The dominant negative mutant cSMRT, which only contains
the nuclear receptor interaction domain, antagonizes tran-
scriptional repression by Ga14-RAa fusion protein (1). Be-
cause cSMRT is located primarily in the cytoplasm, we specu-
lated that this cytoplasmic cSMRT might either sequester
unliganded Ga14- RAa in the cytoplasm or be translocated into
the nucleus by GaI4-RAa. This was tested by double immu-
nofluorescence staining of cSMRT and Ga14-RAa (Fig. 3B). 
previously reported, Ga14-RAa alone was located exclusively
in the nucleus (data not shown). Remarkably, cSMRT seques-
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FIG. 2. Subcellular localization of
ful-length SMRTe and SMRTe frag-
ments. HeLa cells were transient trans-
fected with SMRTe, SMRT, cSMRT, or
HA-tagged deletion mutants shown in
Fig. lA. Immunohistochemistry was con-
ducted with rabbit anti-SMRTe poly-
clonal antibodies , d
, g, 
and h), mouse
anti-SMRTe monoclonal antibodies (i), 
mouse anti-HA monoclonal antibodies 
, e f). The rabbit primary antibodies
were detected by fluorescein-coupled goat
anti-rabbit secondar antibodies (green).
The mouse primary antibodies were de-
tected by goat anti-mouse rhodamine-cou-
pled secondary antibody (red). No colocal-
ization was observed in the double
labeling of SMRTe and the SC35-labeled
splicing speckle (h), or SMRTe and the
Dax-labeled promyelocyte nuclear do-
main (i). The endogenous SMRTe speckle
staining is also shown (j).
tered the Ga14-RAa to the cytoplasm in the absence of ligand
(a-c),and all-trans-RA treatment partially released this se-
questration, rendering accumulated nuclear localization of
Ga14-RAa (d-f). These data suggest that SMRTe can interact
with unliganded RAa in vivo and that atRA can disrupt this
interaction. These data also suggest that cellular compartmen-
talization may contribute to the dominant negative effect of
cSMRT.
Interactions of SMRTe with Class I HDACs- Transcriptional
repression by the unliganded nuclear receptors involves the
recruitment of HDACs to target promoter by the corepressors.
Biochemical evidence suggests that HDAC1 and 2 and mSin3A
form a complex in vivo (22-24). SMRT and N-CoR also form a
complex with mSin3A and HDAC1 and 2 (10-12). Nonetheless
the purified complexes mSin3A.HDAC1 and mSin3A.HDAC2
do not contain SMRTe or N-CoR (24), and SMRTe and N-CoR
complexes contain only HDAC3 (25-27). To understand this
complexity and also to characterize potential SMRTe interac-
tions with class I HDACs , we analyzed their association in vivo
(Fig. 4A). In the absence of SMRTe , HDACs 1 , 2, and 3 were
located diffusely in the nucleoplasm i). Interestingly,
coexpression of SMRTe caused a distribution of HDAC1 (b-
and HDAC3 
(j-
l), but not HDAC2 if- h) or mSin3A (n-
p) 
distinctive SMRTe nuclear speckles. We noted that HDAC3
coexpression appeared to partially distort the structure of the
SMRTe nuclear speckles. Because SMRTe colocalizes with
HDAC1 and HDAC3 in the absence of mSin3A, and because
SMRTe does not colocalize with mSin3A, these data suggest a
mSin3-independent mechanism of interaction between SMRTe
and HDAC1 and 3 in vivo.
To further analyze the interaction between HDAC1 and
SMRTe, we tested this colocalization with three HDAC1 point
mutants whose HDAC enzymatic activities have been dis-
rupted to various degrees (15). The HDAC enzymatic activity
depends on conserved residues within the catalytic domain
and point mutation of these residues disrupts HDAC activity
(15). Three HDAC1 point mutants , H141A, H199A, and D176N
that are either partially defective (H141A) or completely void
(H199A and D176N) ofHDAC activity were analyzed (Fig. 48).
We found that only the partially defective mutant H141A re-
mained associated with SMRTe nuclear speckles in this assay
(a-c), whereas both H199A (d-f) and D176N 
(g-
i) mutants
which lack HDAC activity completely, failed to interact with
SMRTe. These data indicate that the enzymatic activity of
HDAC1 maybe critical in the recruitment ofHDAC1 to SMRTe
nuclear speckles.
Interaction ofSMRTe with Class II HDACs-Recently, mem-
bers ofthe class II HDACs were identified as proteins that also
interact with SMRT (13 , 14). We sought to confirm these inter-
actions in vivo in the double immunofluorescence assay (Fig.
5A). Consistent with a previous report (17), HDAC4 alone was
located primarily in the cytoplasm (a). Strikingly, cotransfec-
tion with SMRTe enhanced translocation of HDAC4 from the
cytoplasm into the nucleus, where it colocalized precisely with
the SMRTe nuclear speckles (b- d). We estimated that, in the
absence of SMRTe , about 70% ofthe transfected cells contained
dormant cytoplasmic HDAC4, and 30% contained approxi-
mately equal HDAC4 staining in the cytoplasm and nucleus
SMRTe Inhibits MEF2C Transcriptional Activation
SMRTe RARa Merged
FIG. 3. Ligand-independent colocal-
ization of RAa with SMRTe. 
SMRTe sequesters RA", in the cytplas-
mic speckles in the absence (-) (a-c), but
not the presence ( + ), of atRA (d-f). SMRTe
and HA-tagged hRA", were double-la-
beled with rabbit anti-SMRTe and mouse
anti-HA antibodies , followed by fluorescein
(geen) or rhodame (red)-coupled second-
ar antibodies , respectively. HeLa cells
were transiently transfected with pCMX-
hSMRTe and pCMX-hR", followed by 1
/-M atRA treatment for 24 h before imu-
nostaining. cSMRT sequesters Gal4-
RA", in the cytoplasm in an RA-sensitive
maner. pCMX-cSMRT and pCMX-Gal4-
RA", were cotransfected in HeLa cells.
Gal4-RA", was detected by mouse anti-
Gal4 DNA bindig domai monoclonal an-
tibodies (red) and the cSMRT with rabbit
anti-SMRTe polyclonal antibodies (geen).
+RA
+RA
(Fig. 5B). Strikingly, coexpression of SMRTe translocated 92%
of HDAC4 into nuclear speckles, suggesting a mechanism of
SMRTe-dependent nuclear import and nuclear domain target-
ing of HDAC4. This SMRTe-mediated nuclear import of the
wild type HDAC4 was even more pronounced than the HDAC4
mutation S246A/S467 A/S632A that abolishes 14- 3 binding in
the cytoplasm (17). The HDAC4 S246A/S467A/S632A mutant
also colocalized with SMRTe nuclear domain (data not shown),
suggesting SMRTe may playa role in the cytoplasmic-nuclear
domain traffcking of HDAC4.
Similarly, we analyzed the colocalization of HDAC5 and
SMRTe by double immunofluorescence assay. HDAC5 alone
was located diffsely in the nucleoplasm (Fig. , e). There
were only about 4% of HDAC5-transfected cells that contained
dominant cytoplasmic staining (Fig. 5C). Strikingly, coexpres-
sion of SMRTe translocated HDAC5 almost completely from
diffuse nucleoplasm staining into nuclear speckles (Fig. 
Fig. 5C), again suggesting a SMRTe-dependent nuclear
domain targeting ofHDAC5. We also tested the interaction of
SMRTe with HDAC6 and found that HDAC6 was located ex-
clusively in the cytoplasm and did not show interaction with
SMRTe (Fig. , i-l). Overall, it can be concluded that SMRTe
selectively interacts with certain members of class II HDACs
and it may play an important role in regulating nuclear import
ofHDAC4 , as well as nuclear domai targeting ofHDAC4 and 5.
SMRTe Enhances HDAC4/ 5-mediated Transcriptional Inhi-
bition on MEF2C-MEF2C-mediated transcriptional activa-
tion is required for muscle cell differentiation, and such tran-
scriptional activation is inhibited by overexpression of HDAC4
and 5 (28). Because SMRTe enhances translocation of cytoplas-
mic HDAC4 into the nucleus, where HDAC4 can interact with
24181
MEF2C and inhibit its transcriptional activity, we speculated
that SMRTe might facilitate the abilty of HDAC4 to inhibit
MEF2C function by promoting nuclear localization of HDAC4.
This possibility was tested by cotransfection of SMRTe and
HDAC4 to determine their effects on MEF2C-dependent acti-
vation of a luciferase reporter gene (Fig. 6). Consistent with
previous findings (18, 29, 30), we found that MEF2C alone
strongly activated reporter gene expression 40- to 100-fold and
that HDAC4 and 5 inhibited this activation by 2- and 4-fold
respectively. In contrast , HDAC1 , 2 , 3 , and 6 did not have much
effect on MEF2C function. On the other hand, SMRTe alone
also had only minor effect on the MEF2C activity (Fig. 6B).
However, cotransfection of SMRTe and HDAC4 synergistically
inhibited MEF2C activity by 20-fold. Similar effect was ob-
served by coexpression of SMRTe and HDAC5 , demonstrating
that SMRTe may synerg:zewith HDAC4 and 5 to inhibit MEF2C-
dependent transcriptional activation of target promoter. There-
fore , the inhibition of MEF2C transcriptional activation ap-
pears to correlate well with targeting of HDAC4 and 5 to
SMRTe nuclear domains.
DISCUSSION
The corepressors SMRT and N-CoR interact with DNA-
bound nuclear receptors to mediate transcriptional repression
by a mechanism involving histone de acetylation. In this study,
we have analyzed the subcellular localization and expression of
full-length SMRTe and characterized the association ofSMRTe
with RAO' and HDACs in vivo. We found that SMRTe is
localized within discrete cytoplasmic and nuclear speckles , and
such localization results in recruitment of unliganded RAO'
and selective HDACs to these nuclear domains. Recruitment of
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FIG. 4. SMRTe recruits HDACI and HDAC3 into nuclear speckles but not HDAC2 or mSin3A.A
, SMRTe was transfected into HeLa cellstogether with HA-tagged HDAC2 , HDAC3 , or FLAG-tagged HDACI or mSin3A and double-labeled by rabbit anti-SMRTe and mouse anti-HA oranti-FLAG antibodies. Panels a and show transfections of each HDAC or mSin3A alone. We found that
, without cotransfection with SMRTeHDACl , 2, and 3 were diffsely distributed in the nucleoplasm i), whereas mSin3A alone displayed a fine speckled pattern (m). Cotransfectionwith SMRTe recruts HDACI (b- d) and HDAC3 
(j-
l), but not HDAC2 if- h) or mSin3A (n-
p) 
into nuclear speckles. histone deacetylase activityis required for localization ofHDACl to SMRTe nuclear speckles. SMRTe and each HDACI mutant were cotransfected and analyz d as 
inA. Theparially active H141A mutant colocalized well with SMRTe (a- c), whereas the H199A (d-f) and D176N 
(g-
i) mutants, which are void ofdeacetylase activity, did not show colocalization with SMRTe.
HDAC1 to SMRTe speckles depends on its histone deacetylase
activity, suggesting a potential role for SMRTe in regulatinghistonedeacetylation. SMRTe actively translocates HDAC4
from cytoplasm into the nucleus
, and HDAC5 from nucleo-plasm into nuclear speckles. Accordingly, cotransfection of
SMRTe with HDAC4 or 5 synergistically inhibits MEF2C tran-
scriptional activation. These data suggest a novel mechanism
by which SMRTe inhibits MEF2C transcriptional activity by
recruiting HDAC4 and 5 to specific nuclear domains.
SMRTe is a unique full-length corepressor that contains an
extended N-terminal domain longer than the previously re-
ported sequence (4). SMRTe is almost identical to SMRTa (31),
except that it lacks a 17-aa insert at residue 721
, it contains an
extra 8-aa insert at residue 1016
, and it has a correct reading
frame for 5 aa starting from nucleotides 2360
, as well as several
single aa polymorphisms. Our assembled SMRTe vector en-
codes a full-length protein in vitro and in vivo that is similar in
size to in vitro translated N-CoR and the endogenous SMRTe.
We also identified a shorter SMRTe message that appears to
contain the conserved SNC-SANT domain. However, it is cur-
rently unclear whether this message represents the reported
SMRTf3 (31) or other members of the SMRT/N-CoR family.
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HDAC4 HDAC5
100 92% 100
0%0%
SMRTe
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FIG. 5. Association of SMRTe with class II HDACs. double immunofluorescence staining of SMRTe and FLAG-tagged HDAC4 , 5 , or 6.
These class II HDACs were transfected alone i) or together with SMRTe. In the absence of SMRTe , HDAC4 is located primarily in the
cytoplasm (a). Coexpression with SMRTe translocates HDAC4 ITom cytoplasm into the nucleus (b- d). SMRTe also recruts HDAC5 ITom diffse
nucleoplasmic stainig (e) into nuclear speckles if- h). SMRTe did not recrut the cytoplasmic HDAC6 into the nucleus (i-l). B quantitation of the
relative localization of HDAC4 , HDAC5, and HDAC6 in the absence (-) or presence ( +) of SMRTe coexpression. The localizations of each HDAC
shown in were quantitated by recording transfected cells with specific localization patterns. 
Cyto indicates cells with predominant cytoplasmic
staining; Cyto/Nu indicates cells with both cytoplasmic and nuclear staining; Nu indicates cells with predominant nuclear staining. The nuclear
staining with diffsed or speckled localization is also indicated for HDAC5. The nuclear staining ofHDAC4 in the presence of SMRTe is primarly
in nuclear speckles. About 250 to 350 transfected cells were recorded in each experiment.
Northern blot analysis reveals that the expression levels of
SMRTe and N-CoR are coordinated in different cancer cells
suggesting that these two proteins may fuction together. Re-
cent data also suggest that SMRTe is not suffcient to comple-
ment the function ofN-CoR in mice , because "knock-out" ofthe
CoR gene resulted in embryonic lethality (32), suggesting
that these two corepressors are not functionally redundant.
By indirect immunofluorescence analysis we show that the
full-length SMRTe protein is localized at discrete cytoplasmic
and nuclear speckles. The identity and biological function of
these speckles remains unknown. We found that the N-termi-
nal extended domain and the RD3 of SMRTe are localized
exclusively in the nucleus , suggesting that multiple nuclear
localization signals may be involved in nuclear localization of
SMRTe. In addition to nuclear localization, RD3 also appears
to contribute to speckled nuclear localization. In contrast, RD4
is responsible for speckled cytoplasmic localization, and cSMRT
appears to lack both nuclear and speckle localization signals.
Recently, phosphorylation by mitogen-activated protein ki-
nases has been shown to cause cytoplasmic localization of
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FIG. 6. SMRTe enhances HDAC-mediated transcriptional ini-bition on MEF2C. HEK293T cells were transfected with MEF2C
(0.2 J.glwell) and a MEF2C-dependent luciferase reporter (0.4 J.glwelltogether with each indicated HDAC or empty vector (0.
J.glwell described under "Materials and Methods.
" Note that only HDAC4 and
5 show significant inhbition on MEF2C transcriptional activation. 
coexpression of SMRTe and HDAC4 and 5 synergistically inhibitsMEF2C-mediated transcriptional activation. Transfection was 
con-ducted as in with the addition of SMRTe where indicated at a
concentration of 0.2 J.glwell. SMRTe alone has little effect on MEF2C
activity, whereas cotransfection of SMRTe and HDAC4 or HDAC5
synergistically inhibits MEF2C activation by 20-fold.
SMRT (33), suggesting a complex signaling pathway 
that reg-
ulates SMRTe localization.
The colocalization of unliganded 
RAa with SMRTe in the
cytoplasmic and nuclear speckles confirms the reported inter-
action of these two proteins in vivo. Because RAa alone is
diffusely distributed in the nucleoplasm
, and because the
speckled pattern ofSMRTe is independent ofRAa these data
suggest that SMRTe recruits 
RAa into these speckles. The
dissociation of RAa from the SMRTe cytoplasmic speckles
upon atRA treatment confirms the proposed theory of ligand-
dependent dissociation of RAa from the corepressor. It ap-
pears that the presumed "SMRTe-free RAa can be readilytransported into the nucleus. However
, it is not clear whether
the presence of cytoplasmic 
RAa is due to nuclear export or
regulated import by SMRTe. It is intriguing to note that TRf3
also undergoes a thyroid hormone-enhanced nuclear transloca-
tion (34). Based on these findings it is reasonable to speculate
that SMRTe might be responsible for regulating nuclear-cyto-
plasmic shuttling of unliganded 
TRf3 and RAa. In addition
we found that cSMRT is primarily located in the cytoplasm
where it can block nuclear localization of GaI4-RAa, suggest-ing that cellular compartmentalization may in part contribute
to the dominant negative activity of cSMRT.
Transcriptional repression by DNA binding proteins involves
a series of protein.protein interactions with corepressors such
as SMRT, N-CoR, and HDACs. In this study, we have also
confirmed the interactions of SMRTe with HDAC1
, 3 , 4, and 5;however, we have found that SMRTe does not colocalize with
HDAC2, HDAC6, and mSin3A. Interestingly, SMRTe can re-
cruit the interacting HDACs into discrete nuclear speckles. The
colocalization of HDAC3
, 4, and 5 with SMRTe is consistent
with previous biochemical findings. In particular
, HDAC3 hasbeen shown to form a stable complex with SMRT and N-CoR(25-27), and HDAC3 can be coprecipitated with HDAC4 and 5
(15). The colocalization of SMRTe with HDAC1
, but notHDAC2 or mSin3A, is somewhat unexpected
, because HDAC1has been reported to form a complex with SMRT indirectly via
interaction with mSin3A (10
, 12). Consistent with our findings
mSin3A does not colocalize well with N-CoR (35). Therefore , wesuggest that HDAC1 may interact with 
SMRTe in vivo in an
mSin3A-independent manner. Perhaps protein modifications
or a yet-to-be-identified protein/factor might stabilize this 
vivo interaction between HDAC1 and SMRTe.
Support for an active role of SMRTe in regulating histone
deacetylation comes from observations that localization of
HDAC1 to SMRTe nuclear speckles depends on the histone
deacetylase activity of HDACl. Similarly, it was recently re-
ported that HDAC5 and 7 mutants
, when lacking HDAC activ-ity, as well as the deacetylase inhibitor trichostatin A and
sodium butyrate, can disrupt colocalization of HDAC5 and 7
with SMRTa (36). Together, these data suggest an important
role for SMRTe/a in organizing a novel nuclear domain that
may be implicated in histone de acetylation and transcriptional
repression.
Finally, we have revealed a functional interaction between
HDAC4 and SMRTe, suggesting a new role for SMRTe in
regulating cytoplasmic-nuclear traffcking, which might be in-
dependent of its nuclear corepressor function. In the absence of
SMRTe, HDAC4 is localized in the cytoplasm due to 14-
binding (17). SMRTe induces a dramatic translocation of the
cytoplasmic HDAC4 into the nucleus. In the nucleus
, HDAC4
can interact with MEF2C and inhibit its transcriptional activ-
ity that is required for muscle cell differentiation (17). Indeed
coexpression of SMRTe and HDAC4 abolishes MEF2C tran-
scriptional activity. This synergistic inhibition is likely due to
enhanced accumulation of HDAC4 in the nucleus. Contrasting
to HDAC4, HDAC5 is distributed diffsely in the nucleoplasmin the absence of SMRTe
, consistent with its stronger inhibi-
tory effect on MEF2C activity. We have found that SMRTe also
recruits HDAC5 into nuclear speckles
, correlating with an en-
hancement of HDAC5-mediated transcriptional inhibition on
MEF2C function by SMRTe. This observation suggests that
HDAC5 localization to SMRTe nuclear domains might furthersuppress MEF2C activity. Because SMRTe also recruits
HDAC4 into the nuclear speckles
, it is conceivable that SMRTe
nuclear domains may play an active role in antagonizing tran-
scriptional activation.
It was reported recently that HDAC4 and 5 are exported
from the nucleus during muscle cell differentiation via a proc-
ess controlled by calcium/calmodulin-dependent protein ki-
nases (37). Thereby, phosphorylation of HDAC4 and 5 and/or
SMRTe by calcium/calmodulin-dependent protein kinasesmight disrupt HDAC.SMRTe interaction
, leading to segrega-
tion and subsequent export ofHDAC4 and 5. Alternatively, this
signal-dependent phosphorylation event might trigger nuclear
export ofthe entire SMRTe.HDAC complex. Although it is clear
that nuclear export of HDAC4 and 5 accompanies MEF2C
activation and muscle cell differentiation
, little is known abouthow HDAC4 and 5 are imported and maintained in the nu-
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cleus. Our data suggest, for the first time, a mechanism of
SMRTe-mediated nuclear import of HDAC4 and nuclear do-
main targeting of HDAC4 and 5. We believe that this mecha-
nism may provide an important piece of the puzzle for under-
standing signal-dependent muscle cell differentiation.
Consistently, N-CoR interacts with MyoD and inhbits muscle
cell differentiation (38). Therefore, it is reasonable to speculate
that nuclear receptor corepressors may enhance transcrip-
tional repression by targeting selective HDACs to specific nu-
clear domains, leading to long-term repression of muscle-spe-
cific genes. We speculate that this strategy may be prototypic
for regulating the activity of other SMRTe-interacting proteins
and it now poses the challenge to further define the exact
mechanism of gene regulation by the SMRTe nuclear domains.
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Steroid/nuclear hormone receptors are ligand-
dependent transcriptional reguators that control gene
expression in a wide array of biological processes. The
transcriptional activity of the receptors is mediated by
an N-terminalligand-independent transcriptional acti-
vation fuction AF- I and a C-terminalligand-dependent
transcriptional activation fuction AF-2. The nuclear
receptor coactivator RAC3 (also known as AIBI/ACTRI
pCIPflRA-I/SRC-3) is amplified in breast cancer cells,
where it forms a complex with estrogen receptor (ER)
and enhances AF-2 activity of the receptor. Here, we
identify a putative human homologue of the yeast DNA
repair and transcriptional reguator MMSl9 as a RAC3-interacting protein. The human MMSl9 interacts with
the N-terminal PAS-A/ domain of RAC3 in vivo and 
vitro through a conserved C-terminal domain. Interest-
ingly, the human MMSl9 also interacts with estrogen
receptors in a ligand-independent manner but not with
retinoic acid receptor or thyroid hormone receptor.
Overexpression of the interacting domain of hMSl9
strongly inhibits ER-mediated transcriptional activa-
tion, indicating a dominant negative activity. In con-
trast, over expression of the full-length hMSl9 en-hances ER-mediated transcriptional activation. We findthat hMSl9 stimulates the AF-I activity of ERa, but
not the AF-2 activity, suggesting that hMSl9 may be an
AF-I-specific transcriptional coactivator of estrogen
receptor.
Steroid/nuclear hormone receptors (SNR)l are ligand-
dependent transcriptional regulators that control gene expres-
sion in a wide array of biological processes such as development
and reproduction (1 , 2). These receptors share a common do-
main structure: an N-terminalligand-independent transcrip-
tional activation function (AF- , or Al region), a centrally
* This work was supported by a National Institutes of Health Grant
DK52888 (to J. D. C. ). The costs of publication of this aricle were
defrayed in part by the payment of page charges. Ths article must
therefore be hereby marked advertisement" in accordance with 18
C. Section 1734 solely to indicate this fact.
The nucleotide sequencers) reported in this paper has been submitted
to the GenBank EBI Data Bank with accession number(s) AF357881.
:j To whom correspondence should be addressed: Dept. of Biochemis-
try and Molecular Pharmacology, University of Massachusetts Medical
School, 55 Lake Ave. North, Worcester, MA 01655. Tel. 508-856-1481;
Fax: 508-856-1225; E-mail: don.chen massmed.edu.1 The abbreviations used are: SNR
, steroid/nuclear hormone receptor;
SRC , steroid receptor coactivator; ER, estrogen receptor; bHLH, basic-helix-loop-helix; PAS , Per-Art-Sim; GST, glutathione transferase;
, hemagglutinin; kb, kilobase(s); PAGE , polyacrylamide gel electro-
phoresis; E2 , 17J3-estradiol; MMS , methyl methanesulfonate; LBD, Li-gand binding domain; hERa, human estrogen receptor; RA, retinoic
acid receptor; TR, thyroid hormone receptor.
located DNA binding domain (or C region), and a C-termnal
ligand-dependent transcriptional activation function (AF-
LBD, or ElF domain). The AF-1 and AF-2 function together to
regulate gene expression in a cell-type-specific and promoter-
specific manner (3-6). However, the exact mechanism is cur-
rently unclear.
Several transcriptional coactivators for SNR have been iden-
tified, including the steroid receptor coactivator (SRC)/p160
family (9), which contains SRC-1 (10), GRIPlfIF2 (11-13),
and RAC3/AIBlJACTRlpCIP (14-18). The SRC/p160 family of
coactivators binds to a hydrophobic pocket on the surface of the
receptor LBD in a ligand-dependent manner (19, 20). The co-
activator enhances transcriptional activation of the receptor
via a mechanism involving histone acetylation and recruitment
of additional coactivators such as CBP/p300 and P/CAF (21
22). Genetic studies demonstrate that SRC- l and RAC3 (pCIP)
are involved in regulating hormonal responses in mice (23-25).
Interestingly, the SRC/p160 coactivators also interact with the
AF-1 domain of several SNRs in a ligand-independent manner
26-30). For ERJ3, such interaction is regulated by phospho-
rylation of the AF-1 region, suggesting that SRC/p160 coacti-
vators may be involved in cross-talk between AF -1 and AF -2 of
the receptor (26-28). RAC3 (AIB1) is unique among the SRC/
p160 family of coactivators, because it is amplified and overex-
pressed in a subset of breast cancers (16). It has been demon-
strated that RAC3 (AIB1) activators form a stable complex
with ERa in MCF-7 breast cancer cells (31), suggesting that
RAC3 may play an important role in regulating ER function 
vwo.
The SRC/p160 co activators share a common domain struc-
ture, including a highly conserved N-terminal basic-helix-Ioop-
helix (bHLH) and Per-Arnt-Sim (PAS) domains (9). The PAS
domain can be subdivided into A and B regions. This domain is
highly conserved among several Drosophila and mammalian
proteins, including Per, Sim, and Arnt (32), as well as in many
regulators of circadian rhythm and neural development (for a
review, see Ref. 33). The bHLH-PAS domain of Drosophila
proteins plays an important role in mediating protein-proteininteraction (34-36). However, the function of the bHLH-PAS
domain of the SRC/p160 coactivators remains largely un-
known. Here, we report the identification of a human homo-
logue of the yeast MMS19 as an RAC3-interacting protein
isolated in a yeast two-hybrid screening with the bHLH-PAS
domain ofRAC3 as bait. Interestingly, hMMS19 also interacts
with ERs in a ligand-independent manner. Our data suggest
that hMMS19 may function as an AF-1-specific transcriptional
coactivator of ER.
MATERIAS AN METHODS
Plasmids-The DNA fragments encoding varous N-terminal do-
mains of human RAC3 (14) were amplified by polymerase chain reac-
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tion with the Pfu DNA polymerase (Stratagene, Inc.). The amplified
DNA fragments were subcloned into pGBT9 vector (CLONTECH, Inc.
for expression of Gal4 DNA binding domain-RAC3 fusion proteins in
yeast, or into the pGEX-2T vector (Amersham Pharmacia Biotech) for
expression of GST fusion proteins in Escherichia coli. The polylinker
regions of these constructs were confirmed by DNA sequencing. Detail
information of these constructs and the polymerase chain reaction
primers used in this study are available upon request.
Yeast Two-hybrid Screening-The yeast two-hybrid screening was
conducted as described previously (14). Briefly, the pGBT-RAC3-
(amino acids 1-408) was used as bait to screen a human placenta cDNA
library (CLONTECH, Inc. ). Positive clones were isolated and tested for
J3-galactosidase expression. Library plasmids were recovered and tested
with various baits to confirm specificity of the protein-protein interac-
tions. The RAC3 screening clone 2. 1 (RS2. 1) showed homology with the
yeast MMS19 protein and was fuher analyzed in this study.
Rapid Amplification of cDNA Ends-The human MMS19-specific
primer (CAT AAG ATA GGA GAT CTG GCT GGG CAC CCAAGA CTG
TC) was used to amplifY the extreme 5'
-end of the hMMS19 cDNA from
a HeLa cell Marathon-ready cDNA along with an adaptor prier from
the manufacturer (CLONTECH, Inc. ). The resultant product was re-
amplified and subcloned into pBluescript II SK + and sequenced.
Construction of hMMS19 Expression Plasmids-The RS2. 1 insert
was released with SalI/BglII and subcloned into the pCMX-HA vector.
pCMX-HA-hMMS19mt was constructed by assembling the SalIBglI
fragment of the longest RACE clone and the BglIINsiI fragment of
GenBank"" accession number AF007151 (Research Genetics) together
with a SalINsiI fragment of the RS2. 1 clone. The pCMX-HA-hMMS19
was obtained by replacing the Dra3/NsiI fragment of pCMX-HA-
hMMSI9mt with the same fragment from the expressed sequence tag
clone BE206052 (GenBank accession number). All constructs were
confirmed by DNA sequencing.
Northern Blot-Multiple Tissue Northern blots (CLONTECH) were
probed with a 32 labeled NsiI/BglI 1.5-kb fragment of hMMS19. Hy-
bridization was performed using the ExpressHyb solution (CLON-
TECH). The blot was washed twice for 20 min in 2x SSC/0. 1% SDS at
room temperature and subjected to autoradiography at - 70 o
GST Pull-down Assay-GST fusion proteins were expressed in E. coli
BL-21 cells and purified by glutathione agarose beads (Amersham
Pharacia Biotech). Labeled proteins were made by in vitro tran-
scription/translation reactions using the T7 
-Quick reticulocyte lysate(Promega). For GST pull-down assay, 5 ILg of bead-conjugated fusion
protein was incubated with 5 ILl of in vitro translated Iabeled pro-
tein with moderate shakng at 4 oC overnight in binding buffer as
previously described (37). The pellet was washed four times with the
binding buffer. Supernatant was removed, and bound protein was
eluted in SDS sample buffer by boiling. The complex was then analyzed
by SDS-PAGE and autoradiography.
Cell Culture and Transient Transfection Assays-HEK293 cells were
maintained in Dulbecco s modified Eagle s medium supplemented with
10% fetal bovine serum. One day before transfection, cells were seeded
in 12-well plates at 50 000 cells per well in phenol-red free Dulbecco
modified Eagle s medium supplemented with 10% charcoal resin-
stripped fetal bovine seru. Transfection was performed using a stand-
ard calcium/phosphate method as described before (37). Afer transfec-
tion, cells were washed with phosphate-buffered saline and re-fed with
fresh medium containing either vehicle alone or vehicle plus ligands.
Cells were lysed 24 h after treatment and assayed for luciferase and
J3-galactosidase activities.
RESULTS
Isolation of a Putative Human MMS19 in Yeast Two-hybrid
Screening-To identify proteins that interact with the bHLH-
PAS domain ofRAC3 , we conducted yeast two-hybrid screening
with the RAC3- terminal domain as bait. The RS2. 1 clone
showed strongest interaction. Sequence analysis and data base
search revealed that RS2. 1 encodes a C-terminal 164-amino
acid polypeptide that shares homology with the yeast MMS19
(38). The full-length cDNA of RS2. 1 was obtained, and it pre-
dicts an open reading frame of 1030 amino acids (Fig. lA). The
full-length RS2. 1 is named hMMS19 because it is related in
size and sequence to the yeastMMS19. We also found a mutant
cDNA clone in the GenBankGB (accession number AF007151),
which contains a single deletion at nucleotide 2240, resulting in
a truncation mutant at 779 amino acids. We designate this
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truncation mutant as hMMSI9-mt. Comparison of hMMS19
with the yeast homologue shows a 36% overall similarity (or
26% identity). The homology is most striking at the N- and
terminal regions with 61% or 57% similarities , respectively.
Related sequences were also predicted from the genomes of
Drosophila melanogaster, Caenorhabditis elegans and Arabi-
do psis thaliana. Alignment of these sequences indicates that
MMS19 is conserved through evolution at the N- and C-termi-
nal domains , whereas the central region has diverged signifi-
cantly. We also found that the hMMS19 gene resides in a
genomic clone (RPll-445I23 , accession number AL359388),
which maps to chromosome 10q24. Interestingly, loss of het-
erozygosity in this region was observed in several human can-
cers, including endometrial and prostate carcinomas (39 , 40).
Northern blot analysis of hMMS19 in various human cancer
cells revealed a single transcript of about 4 kb (Fig. lB top).
The size of this message is in agreement with the length of the
hMMS19 cDNA. The hMMS19 transcript was detected in all
cancer cell lines analyzed as well as in several human tissues
such as heart, brain, placenta, liver, skeletal muscle , and kid-
ney (data not shown), suggesting that hMMS19 is ubiquitously
expressed. Furthermore, by indirect immunofluorescence, we
found that hMMS19 is located in the cell nucleus (Fig. lC). This
nuclear localization is consistent with the hypothesis that
MMS19 is involved in DNA repair and transcriptional
regulation.
Interactions of hMMS19 with RAC3- To further analyze the
interaction of hMMS19 with RAC3, we first tested the speci-
ficity of RS2.1 interactions with various baits in a yeast two-
hybrid assay (Fig. 2A). As expected, RS2. 1 alone did not acti-
vate reporter expression nor did the bait RAC3-N or other
unrelated baits. Coexpression of RS2. 1 with RAC3-N strongly
activated reporter expression as expected. In contrast , RS2.
did not interact with the bHLH-PAS domain of mouse Sim2
(Sim-N) nor did it interact with RAa or p53. These data
confirm that RS2.1 interacts specifically with RAC3-N in the
yeast two-hybrid assay.
We then mapped the RS2. interacting region within the
bHLH-PAS domain ofRAC3 (Fig. 2B). The bHLH-PAS domain
of RAC3 was subdivided into bHLH, PAS- , PAS- , or PAS-
A/ (Fig. 2F) and tested for interactions with RS2.1 in a similar
assay. As expected, none of these baits alone activated reporter
expression (data not shown). Coexpression ofRS2. 1 with PAS-A/ or RAC3-N each strongly activated reporter expression
whereas coexpression with bHLH, PAS- , or PAS-B did not
activate reporter expression in this assay. These data suggest
that the PAS-A and PAS-B domains are both required for
strong interaction with RS2.
To confirm the interaction of RS2. 1/hMMSI9 with RAC3 
vitro we performed a GST pull-down assay using GST fusion of
various RAC3 N-terminal fragments to pull down the 
labeled RS2. 1 fragment or the full-length hMMSI9. The RS2.
fragment and full-length hMMS19 were transcribed/translated
and labeled with ( SJmethionine in reticulocyte lysate. First
the RS2. 1 probe was incubated with GST-RAC3- , and the
bound probe was eluted and analyzed by SDS-PAGE and au-
toradiography. As expected , GST-RAC3- , but not GST alone
pulled down a significant amount of RS2. 1 (Fig. 2C), con-
firming in vitro interaction of RS2. 1 with RAC3-N. Second
hMMSI9 was incubated with GST or GST fusion ofbHLH
PAS- , PAS- , PAS- , or the bHLH-PAS domain of RAC3.
The bound hMMS19 probe was analyzed by SDS-PAGE and
autoradiography (Fig. 2D). As expected , GST or GST-bHLH did
not bring down a detectable amount of hMMSI9. In con-
trast, GST-PAS-A or GST-PAS-B each pulled down a noticeable
amount of hMMSI9, suggesting that hMMS19 can interact
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FIG. 1. Amino acid sequence of human MMS19 and its expression pattern and subcellular localization. 
multiple sequencealignent ofhMMS19 with related sequences of different species by the ClustalW program. The aligned sequences were plotted sing the ESPript
program. Consensus amino acids are boxed and displayed in white against the red background. Highly conserved residues are also boxed anddisplayed in red. The ending sequence ofhMMSl9-mt mutant is indicated
, as well as the staring amino acid of the yeast two-hybrid clone RS2.Amino acid sequences of related proteins in C. elegans, A. thaliana and S. cerevisiae are derived from GenBano: accession numbers T33176BABll076, and NP _012138, respectively. The amino acid sequence of the related protein in 
D. melanogaster is predicted by GENS CAN fromDrosophila genomic sequence AE003603. Four consensus motifs predicted by MEME software are shown under the 
aligned sequences. Northernblot analysis ofthe eXpression pattern of hMMS19 in human cancer cells. f3-Actin is shown as a control. C
, nuclear localization ofhMMSl9. Indirectimmunofluorescence analysis of HeLa cells transfected with HA-hMMSI9 and detected by an anti-HA monoclonal antibody followed by arhodamine-coupled secondar antibody. The 
bottom panel shows nuclear staining with 4' diamidino- phenyl-indole (DAPI) of the same cells.
weaky with PAS-A and PAS-B separately. Interestingly, GST-
PAS-A/ pulled down a much more significant amount of 
hMMS19, suggesting a synergistic effect by PAS-A and PAS-
for binding hMMS19. GST-RAC3-N pulled down an amount of
hMMS19 similar to that of GST-PAS- , confirming that
the bHLH region is not involved in the interaction. The other
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FIG. 2. Interactions of human
MMS19 with RACa in vivo and 
vitro. A yeast two-hybrid interaction of
RS2. 1 with RAC3-N. RS2.1 is expressed
in the pACT2 vector as a Gal4 activation
domain fusion , whereas the baits are ex-
pressed in pGBT vector as Gal4 DNA
binding domain fusion. Vector alone with-
out insert is marked as " " Sim-N con-
tains the bHLH-PAS domain of the Sim.
yeast two-hybrid interaction of RS2.
with various regions of the RAC3 N-
terminal domains , conducted as described
in A. , interactions of RS2.1 with
GST-RAC3-N in GST pull-down assay.
The RS2. 1 polypeptide was translated in
reticulocyte lysate and labeled with
SJmethionie. The RS2.1 was incu-
bated with glutathione agarose beads cou-
pled with GST or GST-RAC3- , and the
bound protein was eluted and analyzed by
SDS-PAGE and autoradiography. in-
teraction of full-length hMMS19 with
RAC3 in GST pull-down assay, conducted
as described in C except that different
GST-RAC3 fusion proteins are used in
this experiment. Coomassie Blue stain-
ing of GST and GST - RAC3 fusion proteins
used in the GST pull-down experiments.
schematic of the RAC3 N-terminal do-
mai fragments used in this study.
t5 25
.s 15
RS2.1: + 
Bait: - 
"" :; 
c. 
.5 
I- 
kDa 
~~~
32.
25-
35S-RS2.
terminal RAC3 fragments, including the nuclear receptor-
interacting domain and the transcriptional activation domain
showed no binding to hMMS19 (data not shown). Therefore
these data are consistent with the above yeast two-hybrid
results in implicating the PAS-AI domain of RAC3 as the
binding surface for hMMS19.
Human MMS19 Interacts with Estrogen Receptor-Because
RAC3 interacts with nuclear receptors, we tested whether
hMMS19 could interact with nuclear receptor in a similar GST
pull-down assay. Intriguingly, we found that GST-RS2. 1 pulled
down a significant fraction (about 20% of input) of ERa in a
ligand-independent manner (Fig. 3A). Similarly, GST-RS2.
also pulled down a significant amount of ER,B (Fig. 3B), sug-
gesting that hMMS19 can interact with both ERa and ER,B.
Similar results were obtained by GST fusion of full-length
hMMS19 (data not shown), suggesting that the interaction also
occur in the context of full-length protein. In contrast, little
interactions of GST-RS2. 1 with hRAa and hTR,B were
detected, consistent with the yeast two-hybrid data. These data
suggest that hMMS19 may also interact with ERa and ER,B.
Human MMS19 Modulates Transcriptional Activity of ER-
The above interactions of hMMS19 with RAC3 and ERs
prompted us to investigate whether hMMS19 could modulate
transcriptional activity of ER. To test this possibility, we per-
formed reporter gene assay by transient transfection in
HEK293 cells. First, we analyzed the effects of overexpression
of RS2.1 on ER-mediated transcriptional activation of a lucif-
erase reporter gene driven by ER-responsive elements (Fig. 4
"nn R) A" pxnpctpd, both ERa and ERa stromdv activated
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RAC3: 't 9:(Q .j 
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luciferase expression in an E2-dependent manner. Cotransfec-
tion with RS2.1 significantly reduced the ligand-dependent
transactivation in a dose-dependent manner without affecting
reporter expression in the absence ofE2. We found that, at the
highest concentration of RS2. , both ERa and ER,B activities
were reduced about 8-fold. Importantly, coexpression of RAC3
can reverse the inhibitory effect ofRS2. 1 on ER transcriptional
activity (Fig. 4C). The inhibition of ER activity by RS2.1 is
specific, for RS2. 1 had no effect on an otherwise identical re-
porter lacking ER binding sites (data not shown). Furthermore,
overexpression of RS2.1 had no effect on ligand-dependent
transcriptional activation ofRAa or TR,B (Fig. il), suggesting
that RS2.1 may selectively affect ER transcriptional activity.
These data are consistent with the preferential interaction of
RS2.1 with ERs but not with RAa or TR,B, implicating that
hMMS19 may playa more important role in regulating ER
activity than RA or TR.
The inhibition ofER transcriptional activity by RS2. 1 may be
explained by the dominant negative effect of RS2. , because
this fragment contains the RAC3/ER-interacting domain. It is
possible that RS2. 1 interferes with the assembly of a functional
ER-coactivator complex. If RS2.1 indeed acts as a dominant
negative mutant, the full-length protein should have a positive
effect on ER transcriptional activity. Indeed, overexpression of
hMMS19 enhanced ER transcription activation in HEK293
cells (Fig. 5A). The moderate effect of this enhancement may be
due to high levels of endogenous hMMS19 in these cells. 
contrast, the hMMS19-mt mutant, which lacks the C-terminal
interacting domain, failed to coactivate ER-mediated transcrip-
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interaction of full-length hERa with RS2. 1 in GST pull-down assay in
the absence or presence of 1 JLM 17/3-estradiol CE2) or 1 JLM dihy-
droxytamoxifen COHT). GST-RS2. 1 pulls down a significant amount of
ERa in a ligand-independent maner. interactions of ER/3,hRa or hTR/3 with GST-RS2. 1 in GST pull-down assay conducted as
described earlier. C, Coomassie Blue staining of GST and GST-RS2.
protein used in the GST pull-down experiments.
tion. Furthermore, coexpression of hMMS19 with RAC3 en-
hanced ER transcriptional activation more strongly than the
expression of each coactivator alone (Fig. 5B), suggesting that
hMMS19 and RAC3 may synergize to stimulate transcriptional
activity of ER.
The above findings suggest that hMMS19 may function as a
transcriptional coactivator of ER. Intriguingly, the yeast
MMS19 has been shown to regulate transcription by influenc-
ing TFIIH activity (38), and TFIIH has been shown to regulate
the AF- 1 function of human ERa (41). To shed light on the
mechanism of MMS19 function in regulating ER activity, we
examined whether hMMS19 affects AF-1 or AF-2 activity of
hERa. We subdivided ERa into the N-terminal AF-1 and the
terminal AF-2 domains , each of which contains the DNA
binding domain. The effect of overexpression ofhMMS19 on the
ERa AF- 1 or ERa AF-2 was then tested by transient transfec-
tion (Fig. 5C). As expected, E2 strongly activated transcription
mediated by the ERa AF-2 but to a lesser extent than the
full- length ERa suggesting that AF-1 is required for maxmal
transcriptional activity of ERa. Cotransfection ofhMMS19 had
no effect on this ligand-dependent transcriptional activity of
ERa AF- , suggesting that hMMS19 is not an AF- dependent
coactivator. As expected ERa AF-1 had a constitutive activity
in the absence of ligand. Addition of E2 slightly enhanced the
ERa AF- 1 activity, presumably due to E2-mediated phospho-
rylation of the ERa AF-1 domain (28, 42). Interestingly, co-
transfection ofhMMS19 strongly enhanced AF-1 activation in
both the absence and presence of E2 by 6.0- and 2. fold
respectively, suggesting that hMMS19 can regulate ER tran-
scriptional activity by stimulating the N-terminal AF-1 func-
tion of ER.
DISCUSSION
MMS19 was initially identified in a yeast genetic screen for
mutations that render cells sensitive to the alkylating agent
methyl methanesulfonate (MMS) (43) and later to UV and DNA
cross-linking agents (44, 45). Analysis of MMS19 mutation in
yeast suggests that it plays a role in nucleotide excision repair
and transcription regulation by affecting TFIIH activity (38
, 47). Here, we isolated a human MMS19 homologue as a
RAC3-interacting protein. Intriguingly, hMMS19 interacts
with both the coactivator RAC3 and the receptor ER and func-
tions as an AF-1-specific transcriptional coactivator of ER.
The bHLH-PAS domain is the most conserved region in the
SRC/p160 coactivators (14); however, the function of this do-
main is largely unknown. The isolation ofhMMS19 as a bHLH-
PAS domain-interacting protein suggests that this domain may
be involved in protein-protein interaction. Further analysis of
the hMMS19-RAC3 interactions reveals that interaction is me-
diated through the PAS-A/ region. Interestingly, strong inter-
action occurs only in the presence of both PAS-A and PAS-
suggesting that there may be two interacting interfaces that
together stabilize the interaction between hMMS19 and RAC3.
The involvement of PAS domain in protein-protein interaction
can also be found in the Drosophila protein Period, which
interacts with Timeless through its PAS domain (48). Because
the PAS domain is highly conserved among the SRC/p160
coactivators, hMMS19 might also interact with SRC-1 and/or
TIF2 , but this remains to be tested. However, despite the
conservation of PAS domains in different proteins , hMMS19
does not interact with the PAS domain of Sim, suggesting the
different PAS domains may be involved with different interact-
ing proteins. The interacting surface in hMMS19 maps to its
terminal conserved domain. Structural prediction suggests
that this region contains multiple potential amphipathic heli-
ces, which might mediate the interaction with the PAS domain
of RAC3.
Analysis ofthe interactions of hMMS19 with nuclear recep-
tors shows strong binding with ERa and ERJ3 in a ligand-
independent manner. Because ER also interacts with RAC3
(49), several possibilties may explain the relevance of these
interactions. For instance, hMMS19 may interact with ER first
in the absence of ligand. This interaction may modulate, for
instance, the phosphorylation states of ER by targeting TFIIH
activity to ER. Upon ligand binding, ER undergoes a conforma-
tional change that allows the receptor to bind the LXL
motifs ofRAC3 via a coactivator-binding pocket in the LBD (9).
RAC3 then interacts with hMMS19 via the N-terminal PAS
domain to stabilze the complex or to signal a subsequent event
in transcription. Alternatively, RAC3 may form a complex with
hMMS19 first, which is then recruited to the liganded receptor.
It is clear that RAC3 uses separate domains for interactions
with hMMS19 and liganded ER. However, it is currently un-
known whether hMMS19 can interact with RAC3 and ER
simultaneously. The fact that the C-terminal domain of
hMMS19 interacts with both RAC3 and ER suggests that the
interactions ofhMMS19 with RAC3 and ERs may be mutually
exclusive. However, it is equally possible that different motifs
in the C-terminal domain ofhMMS19 interact with RAC3 and
ER independently.
The physiological relevance of hMMS19 in ER signaling is
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demonstrated by overexpression ofthe C-terminal RS2.1 frag-
ment and the full-length hMMS19 , each of which significantly
affect transcriptional activity of ER in transfection assays.
Overexpression of RS2. 1 inhibits ligand-dependent transcrip-
tional activation of an ER reporter gene due to a dominant
negative effect. Overexpression of RS2. 1 has no effect on basal
promoter activity in the absence of ligand, consistent with the
observation that ER binds to chromatin in response to ligand
(50 51). AB expected , the full-length hMMS19 enhances ligand-
dependent transcription of the ER reporter gene , whereas the
truncation mutant lacking the RAC3/ER-interacting domain
has no effect on ER activity. Intriguingly, hMMS19 strongly
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enhances the AF-1 activity of ER in both the absence and
presence of ligand and has no effect on the activity of a sepa-
rated AF-2 domain. Therefore, we suggest that hMMS19 func-
tions as an AF-1-specific coactivator of ER. Currently, only a
few potential AF-1 coactivators were reported , such as the p68
RNA helicase (7), and the mechanism of AF-1 coactivator is
largely unknown. The human MMS19 is unique among other
coactivators in that it interacts with both ERs and RAC3.
Because hMMS19 interacts with the PAS domain ofRAC3 and
regulates AF -1 activity of ER, it is intriguing to speculate that
the PAS domain ofRAC3 may be important for regulating AF-
function. However, the mechanisms by which AF-1 activates
transcription and synergizes with AF-2 are largely unknown
and further study is required to fully understand the mecha-
nism of transcriptional activation by nuclear receptors. Our
finding that hMMS19 is an AF- 1 coactivator that also interacts
with AF-2 coactivator RAC3 suggests that hMMS19 may
bridge the functions of AF-1 and AF-
During preparation of this manuscript
, another group re-
ported that hMMS19 interacts directly with the XPD and XPB
subunits ofTFIIH, confirming a regulatory role ofhMMS19 on
TFIIH activity (8). TFIIH is a multiprotein complex consisting
of nine subunits , each participating in transcription and nucle-
otide excision repair pathways. TFIIH harbors several enzy-
matic activities such as a DNA-dependent ATPase linked to
XPD and XPB and a cdk-activating protein kinase
, a cyclin-de-
pendent kinase that phosphorylates the polymerase II C-
terminal tail domain. Recently, it was shown that the AF-
domain of hER is phosphorylated by the TFIIH cyclin-depend-
ent kinase in a ligand-dependent manner (41). Furthermore, it
was shown that phosphorylation of polymerase II C-terminal
tail domain precedes the dissociation of ER/p160 coactivator
complex from target promoters (50). Therefore
, the identifica-
tion of hMMS19 as an ER- and RAC3-interacting protein sug-
gests a novel mechanism by which TFIIH may be recruited to
ER target promoters. In light ofthe important role ofTFIIH in
regulating the transcriptional activity of ER (41), we suggest
that hMMS19 might be involved in regulation ofER activity by
bridging TFIIH with ER. Possibly, the interaction ofhMMS19
with RAC3 might be involved in ligand-dependent recruitment
of TFIIH to ER (41). Alternatively, hMMS19 might facilitate
TFIIH-mediated phosphorylation of ER in specific promoters
and cell types.
In summary, we have identified and characterized the hu-
man homologue of the yeast DNA repair and TFIIH regulator
MMS19 as an RAC3/ER-interacting protein. The humanMMS19 interacts with the N-terminal PAS-AI domain of
RAC3 through an evolutionarily conserved C-terminal domain.
Overexpression ofhMMS19 modulates ER-mediated transcrip-
tional activation by enhancing the AF -1 function of ER. These
data reveal a novel function of hMMS19 as an AF-1-specific
transcriptional coactivator of estrogen receptor.
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